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ABSTRACT 
The therapeutic effect of pulmonary drug delivery systems is limited by its rapid clearance 
from the lungs by robust clearance mechanisms. By controlling the release of drugs, the 
therapeutic effect of pulmonary drug delivery systems, as well as patient convenience and 
compliance could be improved by reducing the number of times drugs need to be 
administered.  
In this study, two controlled pulmonary drug delivery systems for drugs of different 
solubilities were investigated and they were characterised for their viability as effective 
controlled release pulmonary drug delivery systems, particularly in areas of aerosol 
performance and dissolution profile. 
A hybrid protein-polymer controlled release pulmonary drug delivery system was 
developed to sustain the release of a water-soluble anti-asthma drug, cromolyn sodium 
(CS). Two excipients with complementary characteristics – a protein, bovine serum 
albumin, and a polymer, polyvinyl alcohol – were formulated together with CS via co-
spray drying, with varying protein-polymer ratios and drug loadings. The hybrid particles 
showed promise in combining the positive attributes of each excipient, with respirable 
particles shown to sustain the release of CS with a fine particle fraction of 30%. 
Combining the two excipients was complex, with further optimisation of the hybrid 
formulations possible. 
A commercially available polymer, Soluplus® was spray-dried with a poorly-water 
soluble corticosteroid, beclomethasone dipropionate (BDP). The resultant respirable 
powders were shown to have potential for use as a controlled release pulmonary drug 
delivery system with up to 7-fold improvement in the amount of BDP released compared 
to spray-dried BDP. The spray-dried BDP-Soluplus® powders were found to be 
amorphous, and physically stable against re-crystallisation for up to 9 months at 
accelerated stress test conditions with drug loadings of up to 15 % (w/w). Although it 
provided a platform to compare between formulations, the USP 4 flow-through cell 
dissolution apparatus was found to be inadequate to accurately study the dissolution 
profiles of the pulmonary drug delivery systems due to the formation of a gel in the 
apparatus. 
Preliminary work on the use of a novel technique to predict the crystallisation of 
amorphous formulations with terahertz time-domain spectroscopy was also conducted. 
The system confirmed the re-crystallisation tendencies of several hybrid CS/BSA/PVA 
formulations. Modification to the experimental setup to probe the formulations at 
different relative humidities instead of temperatures could yield improved results.
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SUMMARY 
Pulmonary delivery has several advantages such as the localised treatment of respiratory 
diseases, reduction of systemic effects, avoidance of hepatic first-pass metabolism, a large 
absorptive surface with a thin diffusion barrier, as well as a non-invasive route of drug 
delivery. However, the therapeutic effect of inhaled drugs is limited by its rapid clearance 
from the lungs by robust clearance mechanisms such as mucociliary clearance in the 
upper airways, and phaygocytosis in the lower airways. By controlling the release of 
drugs at a rate where there are no initial concentration spikes (which could prompt an 
adverse response) followed by a sharp decline in concentration levels, patient 
convenience and compliance could be improved by reducing the number of times drugs 
need to be administered. Developing cost-effective controlled release pulmonary drug 
delivery systems for the unmet needs of developing countries where the majority of deaths 
from the most common respiratory ailments such as asthma and chronic obstrutive 
pulmonary disease (COPD) occur is also of great importance. Controlled pulmonary drug 
delivery systems could have an outsized effect in those countries, as treatments could be 
administered by non-medically trained professionals, without the use of sterile injections 
and cold chain supply lines.  
In this study, two controlled pulmonary drug delivery systems were investigated, each for 
a different class of drug: a highly water-soluble drug, and a poorly water-soluble drug. 
The controlled release pulmonary drug delivery systems were characterised for their 
viability as effective controlled pulmonary drug delivery systems, particularly in areas of 
aerosol performance and dissolution profile. 
A hybrid protein-polymer controlled release pulmonary drug delivery system was 
developed to sustain the release of a water-soluble anti-asthma drug, cromolyn sodium 
(CS). Two excipients with complementary characteristics – bovine serum albumin (BSA), 
a protein, and polyvinyl alcohol (PVA), a polymer – were formulated together with CS 
via co-spray drying, an industrially scalable formulation process, with different protein-
polymer ratios and drug loadings. While PVA was effective in sustaining the release of 
CS, it tended to form large, hollow and dense particles, which had poor aerosolisation 
ability. BSA was shown to produce small, respirable particles and to improve the fine 
particle fraction (FPF). The hybrid particles showed some promise in combining the 
positive attributes of each excipient, with respirable particles shown to sustain the release 
of CS with a FPF of 30%. The complex process of combining two excipients was 
highlighted, with further optimisation of the hybrid particles possible. 
For the second controlled pulmonary drug delivery system, a commercially available 
amphiphilic graft co-polymer, Soluplus® was spray-dried with a poorly-water soluble 
corticosteroid, beclomethasone dipropionate (BDP). The resultant  powders were shown 
to have potential for use as a controlled release pulmonary drug delivery system with up 
to 7-fold improvement in the amount of BDP released compared to spray-dried BDP. The 
spray-dried BDP-Soluplus® powders were found to be amorphous in nature, while spray-
dried BDP was initially microcrystalline, and BDP had to be cryo-milled for many cycles 
before amorphous powders were produced. The amorphous state, and the dissolution rate 
and solubility enhancement it brings, were maintained over accelerated stress tests for up 
to nine months at drug loadings of up to 15% (w/w). Although it provided a platform to 
compare between formulations, the USP dissolution apparatus 4 (flow-through cell) was 
found to be inadequate to accurately study the dissolution profiles of the pulmonary drug 
delivery systems due to the formation of a gel-phase in the flow-through cell.  
Preliminary work on the use of a novel technique to predict the crystallisation of 
amorphous formulations with terahertz time-domain spectroscopy (THz-TDS) was also 
conducted. The system confirmed the re-crystallisation tendencies of several hybrid 
pulmonary drug delivery systems of CS/BSA/PVA. Modification to the experimental 
setup to probe the drug delivery systems at different relative humidities instead of 
temperatures could yield improved results. 
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Pulmonary delivery is primarily employed to treat respiratory conditions such as asthma, 
cystic fibrosis and obstruction of the lung, but the large surface area of the lungs and good 
epithelial permeability (Patton, (1996)) has also opened up huge potential for the systemic 
delivery of therapeutic agents through the lungs (Patton and Byron, (2007)). The first 
known recording of treatment via inhalation was in ancient Egypt, more than 3,500 years 
ago (Bryan, (1930)). However, the advent of modern inhaled therapy in a form that we 
are familiar with can be linked back to the introduction of the pressured metered dose 
inhaler (pMDI) in 1956 by Riker Laboratories for the delivery of epinephrine and 
isoproterenol (Porush and Maison, (1959); Thiel, (1996)), although the first inhaler was 
thought to have been invented around 1778 by John Mudge (Mudge, (1778)). In the 
1980s, a ban chlorofluorocarbons (CFCs) led to a renewed interest in inhaled drug 
delivery formulation as manufacturers sought out alternative propellants that were safe 
for the environment, and this interest was bolstered by the boom in biotechnology-based 
products. These large macromolecules have been difficult to administer through the 
parenteral and oral routes of administration, leading some researchers to turn to the 
pulmonary delivery route (Kunda et al., (2015)).  
1 INTRODUCTION 
1.1 Pulmonary drug delivery 
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The global impact of lung disease is high. Asthma and chronic obstructive pulmonary 
disease (COPD) are the two most common lung diseases which plague the population 
worldwide. Especially in lower-income countries, access to cost-effective solutions to 
respiratory diseases can reduce its human burden and societal impact (The Global Impact 
of Respiratory Disease - Second Edition, (2017)). An estimated 235 million people in the 
world suffer from asthma and it is the most common chronic ailment plaguing children, 
with 14% of children affected by it. Of the 383,000 asthma-related deaths worldwide in 
2015, most occurred in low or lower-middle income countries (“WHO | Asthma,” 
(2017)). Three million die from another lung disease, COPD, as well each year, making 
it the third leading cause of death worldwide, although more than 90% of the deaths are 
from lower and middle-income countries (“WHO | Chronic obstructive pulmonary 
disease (COPD),” (2016)). These diseases can be controlled effectively using local 
treatment using inhaled devices. Advancements in dry powder inhaler technology have 
produced cheap, disposable dry powder inhalers (Berkenfeld et al., (2015)) which could 
be used as part of a strategy to deliver vaccines and other typically parenterally delivered 
formulations such as oxytocin in the form of heat-stable dry powders using dry powder 
inhalers (Prankerd et al., (2013)), negating the need for cold-chain storage, and bringing 
easier access to greatly needed vaccines for the developing world (Technology Solutions 
for Global Health - Intranasal and Pulmonary Delivery Devices, (2013)). Clearly, cost-
effective strategies for respiratory diseases are necessary but currently still lacking. 
There are several advantages to the use of pulmonary drug delivery, not least for the 
localised action of lung related disorders, avoiding side effects from the systemic delivery 
of therapeutic agents as well the potential to use a lower dose compared to the oral 
delivery route. Drugs delivered through the pulmonary route are also able to circumvent 
hepatic first pass metabolism and have a more rapid onset of action for locally acting 
drugs (Olsson et al., (2011); Pilcer and Amighi, (2010)). For the delivery of systemic 
drugs, pulmonary delivery also offers several advantages such as a large alveolar surface 
area for drugs to be absorbed across a thin epithelial barrier (≤ 0.3-1 μm) into the blood 
stream (Courrier et al., (2002)). Such a delivery route is less invasive than parenteral 
delivery and once again a faster release of drugs can be achieved.  
There are, however, a number of limitations for the delivery of drugs through the 
pulmonary route. Most drugs available in the market are immediate release products. A 
rapid, excessive, initial release of drugs can lead to adverse effects. This is then followed 
by drug release levels that may be too low to be therapeutic (Loira-Pastoriza et al., 
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(2014)). With a successfully designed controlled pulmonary drug delivery system, the 
reduced need to dose frequently can improve patient compliance and convenience, which 
is already greater than that required for oral delivery due to the relatively more complex 
process of administration.  
However, the lung airways offer particular challenges for any pulmonary drug delivery 
system because the airways are highly sensitive to inflammation and they are highly 
efficient at clearing deposited materials. Achieving sustained therapeutic effects requires 
the carrier to pass through the mucus after deposition in the airways, avoid mucociliary 
clearance and rapid absorption. This challenge has yet to be overcome in a clinical setting 
and as a result, there are no commercial systems that offer controlled pulmonary drug 
delivery. 
In the lab, there has been a whole range of different excipients used for pulmonary 
formulations. However, only a handful have been tested and approved for use in humans 
as a result of the difficulty in selecting a suitable excipient that is non-immunogenic, does 
not compromise aerosol performance, and is suitable for controlling the drug release all 
at the same time (Sheth and Myrdal, (2011a)).  
There have been several types of excipients mooted for potential controlled pulmonary 
delivery systems. Liposomes have been known to be biologically inert and thus are a 
promising candidate for the choice of excipient for controlled pulmonary delivery, 
although they are costly, and drug loading into (Beloqui et al., (2013)) and release out of 
these carriers (Lamprecht et al., (2004)) has been found to be tricky. Polymeric systems 
are amongst the most investigated for controlling the release of drugs. They offer a cost-
effective and well-studied route to form particles with suitable properties for controlling 
drug release. However, there are some concerns about their effect on cell viability and 
bioaccumulation (Sheth and Myrdal, (2011b)). 
It is clear that controlled pulmonary delivery to the lung, while desirable, has many 
complex challenges. Different formulation strategies can be adopted to control the release 
of drug in the lung and the characteristics of the drug will also dictate the strategy taken. 
An appropriate strategy can only be decided after considering the fate of the inhaled drug 
in the lung after administration, with knowledge of the physicochemical factors affecting 
deposition in the lung, and the physiology of the lung (Cryan et al., (2007)). 
The human respiratory tract, as seen in Figure 1.1, can be considered to be simply divided 
1.1.1 Physiology of the lung 
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into three compartments of the upper or extrathoracic airways (nasal cavity, nasopharynx, 
mouth oropharynx and larynx), conducting or tracheobronchial airways (trachea, carina, 
hilum, left and right main bronchi) and the alveolated or respiratory airways (bronchi, 
bronchioles, alveoli). Put simply, the lung can be described as a series of bifurcating 
tubes, starting at the trachea and dividing into the bronchi, conducting bronchioles and 
ending in the terminal bronchioles and alveoli. The upper airways help to bring inhaled 
air up to 99% relative humidity (RH) and body temperature. The upper airways also act 
as efficient filters for inhaled particles. 
 
Figure 1.1. Detail of human respiratory system (“Respiratory System,” n.d.) 
A simple, symmetrical model of the lung was proposed by Weibel (Weibel, (1963)) in 
1963 which is still useful today. As seen in Figure 1.2, the modified (2005) model of the 
lung is divided into 23 generations, which split into two branches at each generation. 
Generations 0 to 14-16 are known as the conducting airways, where airflow is by 
convection. The next eight generations are known as the acinar airways, where gas 
exchange with blood occurs. The airway bifurcates an average of 23 times from the 
trachea to the alveolar sacs, representing a circuitous route for any inhaled matter. The 
surface area of the alveolar region is greater than 100 m2 (Stocks and Hislop, (2001)) 
while the rest of the airways only have a surface area of a few square metres. As such, the 
velocity of air declines to very low values in the deep lung. Oxygen is able to diffuse 
through the alveolar epithelium and capillary epithelium. This forms the basis of the 
ability to utilise the lung as an alternative systemic delivery route compared to the 
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traditional routes of gastrointestinal, buccal, transdermal, or nasal delivery (Patton, 
(1996)).  
 
Figure 1.2. Weibel symmetrical lung model of human airway system (Used with 
permission from Weibel et al., 2005) 
The epithelium lining the lungs, bronchi, and bronchioles (airways), and the cells lining 
the alveoli are distinctly different (Figure 1.3). The airways possess a pseudostratified 
epithelium which is lined with three major cell types: goblet (mucus-producing), basal 
(stem or progenitor cells), and ciliated (responsible for mucociliary clearance) (Widmaier 
et al., (2008)). The alveolar epithelium has two different types of cells called 
pneumocytes: type 1, which cover most of the surface and act as a barrier; and type 2 
cells, which produce pulmonary surfactant. The pulmonary surfactant consists largely of 
phospholipids (~85-90%) with the remainder formed by proteins, and is responsible for 
decreasing surface tension in the alveoli (Pérez-Gil, (2008)). Macrophages are also 
present in the alveoli. They are a defence mechanism against foreign matter in the alveoli 
and will engulf and attempt to digest any insoluble particle that deposits in the lung.  
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Figure 1.3. Comparison of lung epithelium at different sites in the lung (Used with 
permission from Patton & Byron, 2007) 
One of the key physicochemical parameters affecting inhalation drug delivery is the 
particle size of the aerosols (defined as a colloidal suspension of particles dispersed in air 
or gas). Particles have to be small enough to get to the deep lung via the mouth, throat, 
and airways, yet not too small that they are exhaled (Byron, (1986); Labiris and Dolovich, 
(2003)). The optimum size range for therapeutic inhaled particles vary but is 
approximately in the range of 2.5-6 µm (Patton, (1996)). The inhaled aerosols are usually 
characterised by an aerodynamic diameter parameter. For a particular aerosol particle, the 
aerodynamic size can be described in terms of a sphere of unit density with the same 
terminal settling velocity as the aerosol particle. This can be described by the following 
equation (Raabe, (1976)):  
 𝑉𝑇  = 
𝜌pg𝑑2𝐶(𝑑𝑣)
𝜅𝑝18𝜂
=
𝜌0g𝑑𝑎𝑒
2 𝐶(𝑑𝑎𝑒)
𝜅018𝜂
 (1) 
Where VT is the terminal settling velocity of the particle; κp and κo are the shape factors 
for the aerosol particle (>1) and an equivalent sphere (=1) respectively; η is the viscosity 
of air; ρp and ρ0 are the densities of the particle and a unit density (1 g/cm3) sphere 
respectively; dv and dae are the geometric and aerodynamic diameter of the particle 
respectively; C(dv) and C(dae) are the slip correction factors for an equivalent volume and 
1.1.2 Physicochemical factors affecting deposition in the lung 
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an aerodynamically equivalent sphere respectively; and g is the acceleration due to 
gravity. 
From Equation 1, we can infer that the particle diameter, density and shape are key 
parameters. The slip correction factors become important for particles smaller than 1 µm, 
which is not common for pharmaceutical aerosols. Hence, since the shape factors are 
important only when the aerosols deviate from sphericity, the equation can be simplified 
as follows for spherical particles:  
 𝑑𝑎𝑒 = 𝑑𝑣√𝜌𝑝 (2) 
The deposition of aerosol particles in the respiratory tract is governed principally by three 
mechanisms – inertial impaction, gravitational sedimentation and Brownian diffusion. 
Inertial impaction occurs when a stream of air containing particles changes direction at a 
bifurcation or airway branch. Particles carrying too much momentum may then impact 
on the walls of the airway. This typically happens for particles with mass median 
aerodynamic diameters (MMAD) – the particle diameter that has 50% of the aerosol mass 
above and below it, greater than 10 µm (Carvalho et al., (2011); Heyder, (2004)) – in the 
upper airways (nose, mouth, larynx and pharynx). Gravitational sedimentation may take 
place when particles between 1 to 8 µm fall by gravity onto the smaller airway walls and 
respiratory bronchioles. Brownian diffusion occurs when particles <0.5 µm are 
bombarded by gas molecules which may direct them towards an airway wall and can take 
place in the alveoli where the air is more stationary. For particles to reach the deep lung, 
aerodynamic diameters between 1-5 μm and below 0.1 μm are preferable (Heyder et al., 
(1986); Schiller et al., (1988)). 
It is important to note the parameters that affect deposition. An increased airflow velocity 
will result in a higher deposition by impaction but decreases sedimentation and diffusion. 
An individual’s breathing pattern also influences deposition. Total respiratory deposition 
increases with tidal volume and residence time of particles in the respiratory tract (Kim 
and Jaques, (2004)).  
Upon deposition in the airways, the fate of the inhaled particle depends on its solubility 
and position in the respiratory tract. Deposition in the lung is a complex combination of 
absorption and the various clearance mechanisms in the lung (Sakagami, (2006)).  
1.2 Deposition and fate of inhaled particles in the lung 
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The lung has developed robust clearance mechanisms to rid itself of foreign objects which 
may enter. Any form of inhalation therapy has to consider these mechanisms and ways to 
elude them. 
Insoluble particles that deposit in the conducting airways get trapped in the mucus layer 
lining it and are then removed by mucociliary clearance (Lansley, (1993)). The ciliated 
cells in the epithelium will be in harmony with neighbouring cilia to drive the insoluble 
or slowly dissolving particle towards the larynx to be expectorated or swallowed (Sleigh 
et al., (1988)). Most particles with geometric diameters above 6 µm will be cleared via 
mucociliary clearance in about 24 hours (Kreyling et al., (2006); Stahlhofen et al., 
(1990)). 
In the alveolar region, slow dissolving and insoluble particles will be cleared by alveolar 
macrophage phagocytosis. Once phagocytosed, the particles are disposed of by 
translocation to the tracheobronchial lymph, digested internally or transported along the 
alveolar surface for clearance via the mucociliary escalator (Labiris and Dolovich, (2003); 
Lombry, (2003)). The process is rapid and almost all particles in the alveoli are 
phagocytosed within 6-12 h of deposition, although there are size-dependent factors for 
this process (He et al., (2010); Lehnert, (1992)). The optimal size for phagocytosis 
appears to be between 1-3 µm (Oberdörster, (1988); Oberdörster et al., (1994)).  
While pulmonary delivery has many advantages, as highlighted earlier, it has to navigate 
the well-adapted lung clearance mechanisms, thus leading to significant drawbacks such 
as the short duration of action and the need to deliver drugs several times a day (Byron, 
(1986)). Techniques to control the release of active ingredients have been in existence for 
many decades in the form of oral sustained release products, fertilisers, and anti-fouling 
agents. Controlled pulmonary drug delivery could offer possibilities for product line 
1.3 Lung clearance mechanisms 
1.3.1 Mucociliary clearance 
1.3.2 Clearance via alveolar macrophages 
1.4 Controlled drug delivery 
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extensions, better clinical response and product development opportunities. However, to 
date, there are no controlled release products for inhalation that are commercially 
available despite significant academic research on the subject (R. Salama et al., (2009); 
Smyth and Hickey, (2011); Uhrich et al., (1999); Zeng et al., (1995)). Some of the main 
challenges behind this are the lack of regulatory approval for excipients that can be 
inhaled to the lung and efficient lung clearance mechanisms (Martonen et al., (2005); 
Patton et al., (2010)).  
As current inhalation therapies require dosages up to four times a day due to short drug 
residence times in the lung (Byron, (1986)), sustaining the release of drugs in the lungs 
will require less frequent dose administration, which can lead to increased patient 
compliance and convenience (Koushik and Kompella, (2004)). Furthermore, a fast 
dissolving drug has low pulmonary selectivity (the amount of drug present in the lung 
compared to systemic circulation) as it will be absorbed into the systemic circulation 
quickly. If the dissolution rate of the drugs can be slowed down, this would increase the 
drug concentration in the lung over a longer period of time compared to that in systemic 
circulation (Issar et al., (2003)). Immediate release also gives rise to an initially high rate 
of release and absorption, followed by a rapid decline, often to below therapeutic levels 
(Ravi Kumar, (2000)). 
Another poignant consideration is that of poor, developing countries. There, access to 
medical supplies that one takes for granted such as sterile needles and clean syringes are 
often difficult, and inhalation therapy offers an opportunity for patients to treat 
themselves safely in a cost-effective manner (Park, (1997)). However, due to reasons 
mentioned above, controlled release in the lung remains one of the biggest challenges for 
inhaled drug delivery (El-Sherbiny et al., (2011)). 
1.4.1 Formulation strategies 
In order for particles to be respirable, they need to be under 5 µm. However, the small 
size of these particles is problematic for sustaining the release of water-soluble drugs as 
there is a significant increase in the surface area-to-mass ratio when the particle size is 
reduced. Consequently, by the Noyes-Whitney Equations (Nernst, (1904); Noyes and 
Whitney, (1897)) (Equations 3 & 4), an increase in surface area entails an increase in the 
dissolution rate. 
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Noyes-Whitney Equation  
𝑑𝐶
𝑑𝑡
= 𝐷𝐴(𝐶𝑠 − 𝐶𝑏) (3) 
Modified Noyes-Whitney Equation 
𝑑𝐶
𝑑𝑡
=
𝐷𝐴𝐾𝑤 𝑜⁄ (𝐶𝑠 − 𝐶𝑏)
𝑉ℎ
 (4) 
Where dC/dt is the dissolution rate of the drug; D is the diffusion coefficient; A is the 
surface area of the solid; Cs the concentration of drug in the stagnant phase; Cb is the 
concentration of drug in the bulk phase; Kw/o is the water/oil partition coefficient of the 
drug; V is the volume of the dissolution medium; and h is the thickness of the stagnant 
layer. 
One of the most established techniques for controlling the release of drugs is to formulate 
them with excipients to prolong the release of drugs in the lungs. The choice of excipients 
depends on several factors such as the physicochemical properties of the drug, type of 
inhaler device used, and carrier properties. 
1.4.1.1 Microparticles 
Polymers have been widely studied for controlled release purposes in all forms of drug 
delivery (Park, (2014)). These carriers typically slow down the rate of release of an active 
ingredient by forming a barrier between the drug and the dissolution fluid (Pilcer and 
Amighi, (2010)). Both natural and synthetic polymers have been investigated for use as 
carriers for pulmonary drug delivery.  
Chitosan is a polysaccharide derived from deacetylation of the naturally occurring 
polymer chitin. It has mucoadhesive properties which lead to its potential for controlling 
drug release. Learoyd et al., (2008) studied the ability for chitosan with different 
molecular weights to sustain the release of terbutaline sulphate and found that high 
molecular weight chitosan was able to display a substantially longer dissolution profile 
compared to low and medium molecular weight chitosan. However, chitosan is prone to 
aggregation and solubility at physiological pH is low. It may not be the most suitable for 
pulmonary delivery as it opens up tight epithelia junctions and may cause pulmonary 
oedema, an abnormal buildup of fluid in the lungs (Yeh et al., (2011)).  
Hyaluronic acid (HA) is another natural polymer which has attracted attention as an 
excipient for controlled pulmonary delivery. It is endogenous to the lung, plays a role in 
inflammatory mediation and is bioadhesive (Rouse et al., (2007)), making in an attractive 
excipient for pulmonary delivery. Surendrakumar et al., (2003), spray-dried hyaluronic 
acid with insulin and found that HA was able to increase both the mean residence time 
and half-life of insulin in beagle dogs.  
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For oral drug delivery, poly(lactic-co-glycolic acid) (PLGA) has emerged as one of the 
foremost polymers in use today, due to its biocompatibility and biodegradability 
(Brannon-Peppas and Vert, (2000); Uhrich et al., (1999)). Naturally, controlled release 
systems for pulmonary drug delivery have also featured PLGA prominently (Beck-
Broichsitter et al., (2012); El-Sherbiny and Smyth, (2012); Hamishehkar et al., (2010); 
Kang et al., (2004); Kim et al., (2012); Lee et al., (2010); Moghaddam et al., (2013); Sun 
et al., (2009)) and it is the most investigated of all polymers for controlled release 
microparticles for pulmonary delivery (Ungaro et al., (2012b)). Doan et al., (2011) used 
a solvent evaporation method to prepare rifampicin-loaded PLGA microparticles and 
were able to release 80% of drug from 12 hours to 4 days. An in vivo study of heparin-
loaded PLGA microparticles prepared by spray drying showed that it was more effective 
to inhibit airway hyper-reactivity than an equivalent dose of heparin solution (Yildiz et 
al., (2012)).  
However, PLGA may not be the most appropriate polymer for use in drug delivery to the 
lung, not least because the degradation period for PLGA microspheres varies between 
weeks to months although it only delivers drugs for a much shorter period of time 
(Batycky et al., (1997)). This could lead to a large, undesired build-up of polymer in the 
lungs (Cook et al., (2005)).  
Exploiting Equation 2, Edwards et al., (1997) developed large porous PLGA particles to 
deliver insulin to rats. The large porous particles had a large geometric size to minimise 
phagocytosis (engulfment followed by digestion) by alveolar macrophages but had a low 
density which resulted in a small aerodynamic size, allowing it to avoid deposition in the 
upper airways and be delivered deep into the lungs. Since then, a wealth of research has 
been conducted on large porous particles using a wide range of porogen (Kim et al., 
(2012); Pham et al., (2013); Vanbever et al., (1999); Yang et al., (2009)). The most 
utilised method to manufacture large porous particles is a double-emulsion process 
(w/o/w), with ammonium bicarbonate and cyclodextrins as popular choices for porogen. 
However, almost all research done on large porous particles for delivery to the lung have 
utilised PLGA as the polymer (Liang et al., (2015)) and as such, the same questions about 
polymer build up is raised.  
1.4.1.2 Large porous particles 
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Figure 1.4. Scanning electron microscope images of doxorubicin-loaded highly porous 
large PLGA microparticles (Used with permission from Kim et al., (2012)) 
Although they present an attractive proposition for controlled release in the lung, large 
porous particles face some barriers to use. Their porosity, which is their defining feature, 
makes their structures more friable and manufacturing difficult to scale. 
With a similar concept to large porous particles, swellable microparticles were developed 
to minimise alveolar macrophage phagocytosis, while still possessing a suitable size for 
delivery into the deep lung (Ibrahim M El-Sherbiny and Smyth, (2010); Selvam et al., 
(2011)). These microparticles have a respirable particle size when dry but swell upon 
contact with the wet lung surfaces. The swollen microparticles are then able to reduce 
macrophage clearance. Swellable microparticles also offer a more controlled architecture 
for drug release than large porous particles (Möbus et al., (2012)). El-Sherbiny et al., 
(2010) prepared freeze-dried microparticles with PEG-grafted chitosan with Pluronic® F-
108 to deliver a model drug, sodium fluorescein. They reported sustained release of up to 
10 or 20 days, in the presence and absence of lysozyme, respectively. Ni et al., (2017) 
1.4.1.3 Swellable microparticles 
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embedded hydrophobic drug nanocrystals into swellable chitosan-based microparticles, 
showing that the technology is also suitable for delivering hydrophobic drugs. 
 
Figure 1.5. SEM micrographs of chitosan-based swellable microparticles over time (Used 
with permission from Ni et al., (2017)) 
Combining two formulation strategies, drug-loaded nanoparticles were embedded in 
swellable microparticles (El-Sherbiny and Smyth, (2012)). They offer a method to deliver 
nanoparticles via dry powder inhalers (DPIs) as DPIs are not able to disperse 
nanoparticles on their own. El-Sherbiny & Smyth, (2010) encapsulated PEG-grafted N-
phthaloyl chitosan nanoparticles into sodium alginate microspheres. The formulation 
showed an initial burst release for the first two hours, followed by a more gradual release 
over four days. 
Swellable microparticles, however, suffer the same drawbacks at traditional 
microparticles in terms of less than ideal fluidisation and dispersibility, and that it may 
be challenging to tune the release of drugs through the swollen microparticles.  
Liposomes are vesicles formed by lipid bilayers and can encapsulate hydrophilic drugs in 
the core and hydrophobic drugs in the lipid bilayers. By the use of rigid phospholipids or 
1.4.1.4 Liposomes 
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cholesterol, a less permeable membrane can be created for drugs to diffuse through (Beck-
Broichsitter et al., (2013)). Liposomes can be prepared using lipids endogenous to the 
lung, such as dipalmitoylphosphatidylcholine (DPPC), the major phospholipid in lung 
surfactant, allowing such liposomes to be very well tolerated by the lung. Liposomal 
formulations are the only sustained release pulmonary delivery products which have 
reached clinical trials (Swaminathan and Ehrhardt, (2011)).  
 
Figure 1.6. Schematic of a typical liposome developed for drug delivery. Peptides can be 
conjugated with the lipids to direct it to a particular location (Used with permission from 
(Bitounis et al., (2012)). 
Arikayce®, liposomal amikacin formulations developed by Insmed are in phase III 
clinical studies for the treatment of nontuberculous mycobacterial lung infection and 
phase II clinical studies for chronic Pseudomonas aeruginosa in non-cystic fibrosis 
bronchiectasis (Ehsan and Clancy, (2015); “Pipeline,” n.d.). Liposomal amikacin was 
able to provide slow sustained release in unaffected rat lungs. It is attracted to the 
negatively charged mucus and biofilms, and are able to deliver high levels of amikacin to 
the infection site, allowing once daily dosing in comparison to free aminoglycoside 
therapy of twice daily dosing of tobramycin.  
Liposomes are widely delivered by nebuliser from a suspension, but long-term instability 
is a concern. Nebulisation can also disrupt the structure of the liposome, causing 
premature release of drug. As such, liposomes have also been formulated into dry 
powders by lyophilisation, spray-drying or spray freeze-drying (Bi et al., (2008); Gibbons 
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et al., (2010); Misra et al., (2009); Tang et al., (2015); Willis et al., (2012)). Another 
important factor to consider for the use of lipids in formulations is the high cost associated 
with the raw materials for the lipid excipients and the high production cost because of 
third party manufacturing (Jeong et al., (2006)). 
Solid lipid nanoparticles (SLNs) were introduced in 1991 as an alternative carrier system 
to systems such as liposomes, emulsions and polymeric particles (Müller et al., (2000)). 
A solid lipid core is stabilised by a surfactant with the active ingredient dissolved or 
dispersed. SLNs are well tolerated by the lungs and are more stable under nebulisation 
compared to liposomes.  
 
Figure 1.7. Structure of a solid lipid nanoparticle (SLN) (Used with permission from (Lin 
et al., (2017)). 
C. Wu et al., (2016) prepared SLNs loaded with a flavonoid compound, naringenin, by 
emulsification and were able to release 80% of the drug over 48 hours with a sustained 
profile. The lyophilised powders were stable at both refrigerated and ambient 
temperatures for three months, and the bioavailability of the drug in Sprague-Dawley rats 
was shown to be 2.5 times greater than that of naringenin suspensions. Zhao et al., (2017) 
prepared essential oil-loaded SLNs by homogenisation and demonstrated extended 
1.4.1.5 Solid lipid nanoparticles 
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pulmonary retention of up to 24 h in vivo, with up to 7.7 fold increase of bioavailability 
compared to the essential oil solution. 
However, SLNs are still a relatively immature technology with many advancements still 
to be made in the field. It also suffers from poor drug loading and potential gelation from 
polymorphism of the solid lipids. 
As mentioned earlier, nanoparticles are not able to be dispersed by dry powder inhalers. 
As with the earlier examples of embedding nanoparticles within swellable microparticles, 
nanoparticles can also be embedded into microcarriers. Tsapis et al., (2002) proposed 
combining the drug release advantage of nanoparticles with the flowability, aerosolisation 
and processing ease of microparticles by spray-drying nanoparticles with large porous 
particles. The large porous particles dissolve to release the nanoparticles, who bear the 
drug release load. 
 
 
Figure 1.8. Mechanism for release of nanoparticles from nanoparticle-embedded 
microparticles in the lung. 
Ungaro, D’Angelo, et al., (2012) developed a pulmonary delivery system of tobramycin-
loaded PLGA nanoparticles embedded in lactose microparticles. The nanoparticles were 
optimised for size and surface properties by the addition of hydrophilic polymers such as 
polyvinyl alcohol (PVA) and chitosan, while alginate enabled the efficient entrapment of 
1.4.1.6 Nanoparticle-embedded microparticles 
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tobramycin and its release for up to one month in vitro. 
Gold nano-in-micro dry powder formulations were investigated for the treatment of lung 
cancer (Silva et al., (2017)). These gold nanoparticle-embedded microparticles were 
functionalised for disease targeting as well as theragnosis and were prepared by 
supercritical CO2-assisted spray-drying. The nanoparticles displayed a sustained and 
controlled release of the gold nanoparticles, with enhanced cellular uptake.  
While nanoparticle-embedded microparticles offer promise as a formulation strategy for 
controlling the release of active ingredients in the lung, redispersal of nanoparticles from 
the microparticles are not well controlled yet, with room for further improvement. 
 
Table 1.1. Comparison of Different Formulation Strategies for Controlled Pulmonary 
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Delivery. 
Formulation strategy Advantages Disadvantages 
Microparticles 
 Straightforward 
manufacturing 
 Mature process 
 Non-ideal fluidisation and 
dispersibility 
 Phagocytosis by alveolar 
macrophages 
Large porous 
particles 
 Reduced phagocytosis by 
alveolar macrophages 
 Better aerosolisation 
properties 
 Poor control of 
encapsulation and release 
 Difficult to scale up 
manufacturing process 
Swellable 
microparticles 
 Reduced phagocytosis by 
alveolar macrophages 
 Non-ideal fluidisation and 
dispersibility 
 Tricky to tune drug release 
Liposomes 
 Biocompatible 
 Reduced phagocytosis by 
alveolar macrophages 
 Able to solubilise poorly 
soluble drugs 
 Expensive 
 Drug leakage due to 
instability 
Solid lipid 
nanoparticles 
 Biocompatible 
 More stable than liposomes 
 Poor drug loading 
 Possibility of gelation 
Nanoparticle-
embedded 
microparticles 
 Reduced phagocytosis by 
alveolar macrophages 
 Redispersal of 
nanoparticles not well 
controlled 
 
There are three main types of inhaler devices for pulmonary delivery: Nebulisers, 
pressurised metered dose inhalers (pMDIs) and dry powder inhalers. When considering 
which type of inhaler device to use, several studies have concluded that there is little 
difference between them and that factors to consider in choosing an appropriate device 
depend not only on physicochemical properties such as drug particle size but also on an 
individual patient’s inspiratory airflow, skill and choice (Bonini and Usmani, (2015); 
Brocklebank et al., (2001); Haughney et al., (2010)). However, dry powder inhalers are 
1.5 Pulmonary delivery devices 
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touted as having the greatest research and development potential for improved pulmonary 
therapy as the newest technology of the three (de Boer et al., (2017)).  
Nebulisers are amongst the oldest devices used for delivering therapeutic agents. They 
are used to deliver a single dose of therapeutic agent in an aqueous medium, usually over 
multiple breaths via tidal breathing. They are typically used for the delivery of 
bronchodilators for those afflicted with asthma or COPD who cannot use other devices 
effectively, such as the elderly and young, as they do not require coordination between 
inhalation and actuation.  
Nebulisers utilise different technologies to deliver drug aerosols and there are three 
commonly used types: jet nebulisers which use compressed air to deliver the drug 
formulation through a spray nozzle; ultrasonic nebulisers which form aerosols from a 
vibrating piezoelectric crystal; and vibrating membrane/mesh nebulisers where the drug 
is extruded through a vibrating membrane or mesh. Jet nebulisers operate by the Bernoulli 
principle (Venturi effect). High pressure compressed gas is passed through a nozzle called 
a venturi. This creates a low-pressure region at the nozzle where a liquid (or suspension) 
drug formulation will be drawn up into the air into droplets. Larger droplets are blocked 
from entering the mouthpiece or facemask by a baffle, which in turn recycles these larger 
droplets to be re-nebulised. 
Nebulisers are easy to use and are able to deliver most drugs in any given dose. However, 
they are bulky to handle and can only deliver single doses and are thus usually limited to 
a hospital or home setting.  
As previously mentioned, modern drug delivery to the lungs was started by the 
commercial availability of pressurised metered dose inhalers (pMDIs) for the treatment 
of asthma by Riker Laboratories in 1956 (Crompton, (2006)). However, the effect of 
CFCs used as propellants in pMDIs on the depletion of the ozone layer hypothesised by 
Molina & Rowland in 1974 prompted their substitution by the relatively more 
environmentally friendly hydrofluoroalkane (HFA) gases as directed by the Montreal 
protocol in 1987 (Handbook for the Montreal Protocol on Substances that Deplete the 
Ozone Layer, (2017)). Since the transition to the new propellants, pMDIs have remained 
1.5.1 Nebulisers 
1.5.2 Pressurised metered dose inhalers 
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a widely used and accepted form of inhalation therapy worldwide (Myrdal et al., (2014)). 
A schematic of a pMDI is shown in Figure 1.9. A canister holds the propellant formulation 
(either a solution or suspension) with a metering valve crimped to its lid. Upon actuation, 
the metering valve releases a known quantity of the formulation. The propellant expands 
when it exits the nozzle, resulting in a fine mist, which is quickly evaporated off to leave 
micron-sized drugs for inhalation. 
 
Figure 1.9. Schematic of the major components of a pMDI (Reproduced from Buddiga, 
(2015)) 
The advantages of pMDIs are that they are portable, easy to handle, capable of delivering 
multiple doses of drug, have better protection against moisture, and have a lower risk of 
bacterial contamination (Newman, (2005)). However, they have a lower capacity than dry 
powder inhalers and are thus able to deliver fewer doses (Traini and Young, (2013)). In 
some instances, patients have had adverse reactions to the Freon propellants used in the 
inhalers  (Oenbrink, (1993)) and some complain of the cooling effect that the rapid 
evaporation of propellant causes (Purewal and Grant, (1997)). However, the greatest 
patient related drawback to pMDIs is that it requires the patient to make a coordinated 
effort to actuate the device and inhale simultaneously, compared to the breath actuated 
DPIs and the tidal breathing regime of nebulisers. The delivery of drugs are highly 
dependent on the inhalation technique and it is possible to get very little drug in the lung 
with poor technique; if the patient inhales before or after actuations, most of the drug will 
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be caught in the throat and swallowed, instead of depositing in the lung (Traini and 
Young, (2013)).  
In order to address these issues, two modifications to classical pMDIs have been adopted: 
the use of spacers and breath-actuated pMDIs.  
A spacer is a device which is attached to the mouthpiece of the inhaler. The aerosol is 
actuated into the spacer first, for the patient to inhale using tidal breathing (normal, 
automatic breathing). Since spacers are add-on devices, they do not require modification 
to an existing pMDI. Being able to inhale the dose via tidal breathing brings benefits to 
certain subpopulations such as children and the elderly. However, whilst still portable, 
spacers can add some bulk to the inhaler device, so convenience is compromised. As 
spacers are another “space” between the inhaler and the patient, it is another item to 
consider when handling the inhaler. Variations in the aerosol cloud and dose could occur 
due to this intermediate “space” (Chew and Chan, (2000)) and these spacers have to be 
maintained in a proper manner to minimise static charge on the inner surfaces of the 
spacers, which could attract particles to it and thus reduce the delivered dose (Anhøj et 
al., (1999)).  
 
Figure 1.10. Schematic of a spacer attachment for a pMDI (“How to Use Your Inhaler,” 
n.d.) 
Breath-actuated pMDIs require modifications to the device, where the canister is held in 
a post-actuated state to be released when the patient inhales. This does away with the need 
to coordinate actuation and breathing but still requires forced inspiration as opposed to 
tidal breathing with the use of spacers. Although fewer patients display improper inhaler 
technique with these devices compared to pMDIs (Lenney et al., (2000)), they require 
greater inspiratory flow compared to pMDIs and also do not solve the issue of the cooling 
effect mentioned above (Lavorini, (2013)).  
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Figure 1.11. Schematic of a breath-actuated pMDI (Autohaler, 3M Pharmaceuticals, St 
Paul, MN, USA) (Used with permission from Newman, 2005).  
Dry powder inhalers were developed to address some of the limitations of pMDIs. Some 
issues arising from the use of pMDIs include low solubility (Smyth, (2003)), crystal 
growth (Phillips and Byron, (1994)), chemical instability (Wu et al., (2012)) of active 
ingredients. DPIs are propellant-free [negating the discussion on the potency of HFAs as 
greenhouse gases, notwithstanding their minuscule contribution to overall greenhouse gas 
emissions (McDonald and Martin, (2000))] and do not require patients to simultaneously 
actuate the device with inspiratory airflow, which could prove difficult for certain patients 
(O’Connor, (2004); Stein et al., (2014)). However, the patient convenience that actuation 
through a patient’s inspiratory airflow brings, also means that the deposition efficiency is 
dependent on individual patients’ inspiratory airflow. Dry powder inhalers can be 
classified as ‘passive’ devices, where DPIs utilise the patient’s inspiratory airflow to 
deliver the medication to the lungs; or ‘active’ devices, where the energy needed to 
1.5.3 Dry powder inhalers 
Chapter 1: Introduction 
Leonard Chia - February 2018   23 
aerosolise the powder comes from an external source such as compressed air or a battery. 
There are more than 20 different commercially available DPIs which are used for local 
and systemic delivery (Valdes et al., (2014)) of active ingredients (Berkenfeld et al., 
(2015)). Recently, low-cost, single-use disposable DPIs have been developed, which 
opens up avenues to the cheap and reliable delivery of vaccines as well as medication for 
rescue operations (Berkenfeld et al., (2015)).  
As mentioned earlier, an aerodynamic diameter of 1-5 µm is required for particles to 
deposit in the small airways and the alveolar regions (Labiris and Dolovich, (2003)). 
However, at these sizes, the micronised powders tend to be cohesive/adhesive and form 
agglomerates due to interparticulate forces such as van der Waals, mechanical 
interlocking, capillary, and electrostatic forces (Telko and Hickey, (2005)). These 
agglomerates have to be deagglomerated before they enter the respiratory system as they 
affect the respirable dose. Traditionally, the micronised powders have been blended with 
a coarse carrier (30-90 µm) such as lactose, to improve flow properties and enhance 
dispersion. However, problems may arise if the carrier is not blended uniformly and if 
there is poor detachment from of the drug from the carrier, while the aforementioned 
interparticulate forces are only reduced and not eliminated (Thalberg et al., (2012)). As 
such, some studies are focused employing particle engineering techniques, such as spray-
drying and wrinkled surfaces, to develop carrier-free formulations for dry powder inhalers 
which reduce the cohesion forces of the particles, while maximising redispersion of the 
powders (Healy et al., (2014)).  
Dry powder inhaler devices can be categorised into three groups: single dose, multi-unit 
dose and multi-dose reservoir systems. Single-unit dose inhalers are the most commonly 
used type of DPI. The patient loads a capsule filled with the micronised powder into the 
DPI and ruptures it before the inhalation manoeuvre. The punctured capsule shell must 
be removed before administrating the next dose. Multi-dose devices come with pre-
metered doses stored in individually sealed packaging such as blister packs or discs, while 
multi-dose reservoir systems contain a reservoir of dry powder which is dispensed by a 
built-in mechanism.  
Single-unit dose inhalers have also been developed as disposable single use devices 
(Friebel and Steckel, (2010)). TwinCaps® inhaler (Hovione, Loures, Portugal) is a 
disposable DPI which has been approved for use in Japan. It is used in the postexposure 
prophylactic treatment of influenza A and B infections. Disposable DPIs also open up the 
potential for the delivery of vaccines in developing countries, where access to sterile 
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medical supplies and uninterrupted cold chain storage conditions may be less than ideal. 
DPIs present a non-invasive delivery route which may be administered by a non-
medically trained person. Disposable DPIs could also be used in the delivery of 
medication in rescue situations. 
As highlighted, the physicochemical properties of aerosol particles play an important role 
in its deposition in the lung. Despite its relatively long history in treating diseases and 
ailments in the lung, there is still much room for improvement for the delivery of active 
agents to the lungs including in the areas of deposition efficiency, targeting and sustained 
or controlled release (Koushik and Kompella, (2004); Smyth and Hickey, (2011)). 
Inhaled drug powders were traditionally produced by crystallising the drug, then milling 
it down to a suitable size. These days, a number of engineering strategies can be employed 
to produce inhalation products, especially in particle engineering where methods such as 
spray freeze-drying and spray-drying could be used to find solutions to the delivery of 
therapeutic agents in the treatments of the pulmonary ailments. Particle engineering 
advancements have enabled the development of pulmonary delivery systems that are 
carrier-free, have biodegradable fine carriers and offer combinational therapy amongst 
others. Particle engineering technology has also been adopted to modify the 
physicochemical properties of the particles, such as density, morphology, surface 
characteristics, and the formation of amorphous and polymorphic forms of active 
ingredients, to achieve improvements in aerosol performance, lung deposition and 
dissolution (Chow et al., (2007)).  
Spray freeze-drying (SFD) is a technology combining spray drying and freeze drying, as 
its name suggests. In SFD, a drug solution is sprayed into the cold vapour above a freezing 
medium (usually liquid nitrogen) to form droplets. The droplets are subsequently 
lyophilised to remove ice and generate powders (Figure 1.12). The process is able to 
produce light particles with virtually 100% product yield. However, it was found that the 
time required for the droplets to freeze and the air-liquid interface formed on the surface 
of the droplets may result in a broad particle size distribution and aggregation (Webb et 
al., (2002); Yu et al., (2006)). Spray freezing into liquid (SFL) was developed to 
1.6 Particle production technologies for pulmonary delivery 
1.6.1 Spray freeze-drying 
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overcome this problem (Hu et al., (2002)). In SFL, the drug solution is sprayed directly 
into the liquid cryogen instead of its vapour, at a faster speed compared to SFD. This 
process produces amorphous powders with a narrow size distribution, high surface area 
and low bulk density exhibiting good flowability (Hu et al., (2003); Rogers et al., (2002)). 
However, the use of cryogens makes it an expensive process, justifiable only for an 
expensive drug. 
 
Figure 1.12. Schematic of spray freeze-drying process. 
In the spray drying process, a drug solution or suspension is passed through an atomising 
nozzle to form fine droplets. These droplets are then rapidly dried by a hot air current to 
form dry powders, which are separated from the air flow by a cyclone into a collection 
vessel (Figure 1.13a). The spray dryer can also be set up to run in a ‘closed loop’ for 
poorly water-soluble drugs, with an inert loop to condense organic solvent vapours 
(Figure 1.13b). 
There is a range of different nozzles which can be used for spray drying: rotary atomisers, 
ultrasonic nozzles, and two-fluid nozzles. Son & McConville, (2012) utilised a three-fluid 
nozzle to simultaneously encapsulate and coat rifampicin particles in a single, continuous 
process for sustained release in the lung. This presents an interesting prospect of 
combining a particle engineering process together with a coating process to minimise 
1.6.2 Spray drying 
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both time and loss of material into a single operation. 
Spray drying has become a standard technique to produce powders for inhalation. It is an 
important tool in the particle engineering field as it offers a facile, one-step process which 
is scalable for larger production while giving one control over the particle size, particle 
size distribution, particle morphology, moisture content of particles and surface properties 
such as particle surface area, which are all important characteristics in any DPI system, 
by tuning the aspirator flow rate, inlet temperature, spray gas flow and feed solution rate 
(Seville et al., (2007); Vehring, (2008)). Spray drying has been employed to produce 
commercially available inhaler products (Carvalho et al., (2015)). 
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Figure 1.13. Schematic of spray dryer in (a) ‘open loop’ and (b) ‘closed loop’ 
configuration. 
(a) 
(b) 
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While spray drying can be used to effectively prepare microparticles, it is unable to do so 
for nanoparticles because of separation and collection limitations (Heng et al., (2011)). 
The nano spray dryer from BÜCHI (Flawil, Switzerland) was developed specifically to 
generate particles with sizes ranging from 300 nm to 5 µm, which is a size range which 
has great potential for the pulmonary field as nanoparticles are able to reduce 
phagocytosis by alveolar macrophages (Todoroff and Vanbever, (2011)). However, it is 
limited by a low throughput and long processing times. The technology is still in its early 
stages and is characterised by high cost (which may go down as the technology matures) 
that may limit its current use to high-value products.   
 
Figure 1.14. Schematic of the laboratory scale Nano Spray Dryer B-90 (Used with 
permission from S.H. Lee et al., 2011). 
 
1.6.2.1 Nano spray-drying 
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The aim of this thesis is to investigate controlled pulmonary drug delivery systems. Two 
systems have been formulated for drugs of different natures: water-soluble and poorly 
water-soluble. The fast release of drugs results in high absorption with high 
concentrations but a short duration of action while overly slow release may result in non-
therapeutic drug levels (Loira-Pastoriza et al., (2014)).  
These systems were designed to be cost-effective for greater access to inhaled therapy 
worldwide, where there is a high incidence of mortality from respiratory diseases and 
where there is an unmet demand for cheap and effective inhaled therapy. Pulmonary 
delivery offers a safe and convenient means of administering medicine without the need 
of a trained medical professional, and controlling the release of the drugs from pulmonary 
delivery systems may enhance patient convenience and compliance.  
To that end, administration of drugs using dry powder inhalers was selected for this study 
as they offer greater physicochemical stability of drugs, the possibility to deliver drugs in 
a cheap, disposable form, and the greatest potential for new, improved therapies (de Boer 
et al., (2017)).  
Spray drying is a mature manufacturing technology which has been applied to produce 
powders for inhalation commercially. It offers a facile, continuous and scalable process 
from feed to dry powder, and hence is ideal for producing inhalable powders.  
More specifically, the objectives can be described as: 
1. Develop controlled pulmonary drug delivery systems with a suitable release rate 
and necessary characteristics for effective pulmonary delivery. 
2. Evaluate the feasibility of using a hybrid drug delivery system to modulate the 
release of a water-soluble drug with the use of two excipients with complementary 
features. 
3. Explore the use of a commercially available amphiphilic excipient, with the ability 
to solubilise poorly water-soluble drugs and form solid solutions, as a strategy to 
formulate poorly water-soluble corticosteroids and increase its dissolution rate in 
the lung.  
4. Study the physical stability of the spray-dried powders. 
1.7 Aims and objectives 
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The formulations were evaluated for their spray-drying yield using the following 
equation: 
 Yield (%) = (
Weight of solids collected from spray dryer
Weight of solids added to spray-drying feed solution
) × 100  (5) 
Weighed amounts of spray-dried powder were dissolved in dissolution medium and left 
to stir for three days. The drug content in the dissolution was analysed either by 
ultraviolet-visible (UV-vis) spectroscopy or high-performance liquid chromatography 
(HPLC) and calculated using the following equations: 
 Drug loading (%)= (
Weight of drug in spray-dried powder
Weight of spray-dried powder
) × 100  (6) 
Entrapment efficiency (%) = (
Weight of drug in spray-dried powder
Weight of drug added to spray-drying feed solution
) × 100  (7) 
Powder X-ray diffractograms were obtained for the co-spray dried particles using an X-
ray diffractometer (D8 ADVANCE, Bruker Corporation, Madison, WI, USA) in steps of 
0.02° using Cu Kα radiation as the X-ray source. The measurement conditions were as 
follows: target, Cu; filter, Ni; voltage, 35 kV; current, 40 mA; scanning speed, 10°/min 
 
2 SCIENTIFIC METHODS 
2.1 Yield, drug loading, and entrapment efficiency 
2.2 Powder crystallinity 
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The moisture sorption properties of the formulated powders were investigated using 
dynamic vapour sorption (DVS) (DVS-Advantage, Surface Measurement Systems, 
London, UK). About 30 mg of powder was used per measurement, subjected to two cycles 
of 0-90% RH with 10% RH steps. The system was considered to have attained 
equilibrium when the rate of change of mass per time (dm/dt) was less than 0.001% per 
step. 
The surface of the formulations was probed by X-ray photoelectron spectroscopy (XPS) 
(also known as electron spectroscopy for chemical analysis [ESCA]) using an ESCALAB 
250 Xi X-ray photoelectron spectrometer microphobe (Thermo Scientific, Waltham, MA, 
USA). The measurements were carried out using an XR6 monochromated Al Kα (1486.68 
eV) X-ray source with a circular analysis spot size of 200 µm at an analysis depth of less 
than 110 Å. The powders were mounted onto adhesive copper tape.  
The surface composition of the powders can be estimated by studying the relative atomic 
concentrations of different elements in the pure spray-dried components and the spray-
dried formulations (Elversson and Millqvist-Fureby, (2005); Fäldt et al., (1993)). 
For 
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For 
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 (9) 
 Or  
 𝐼γ = 𝑓 (10) 
 
where I is the matrix of the elemental composition of the pure components, f is the vector 
containing the elemental composition of a formulation’s surface, and γ the relative 
coverage of the different components. The equation can be solved to find out which 
2.3 Moisture sorption 
2.4 Surface composition 
Investigating Controlled Release Pulmonary Drug Delivery Systems 
32  Leonard Chia - February 2018 
components are on the surface of the formulations using a linear least squares method 
which gives:  
 𝛾 = (𝐼T𝐼)−1𝐼T𝑓 (11) 
To compare the estimated surface coverage results with that of the bulk composition of 
the spray-dried formulations, the estimated molar percentages were converted to mass 
percentages.  
Particle size morphology was examined using a high-resolution field emission scanning 
electron microscope (FESEM, JSM-6700F, Jeol Ltd, Tokyo, Japan). Each sample was 
mounted onto a SEM stub using double-sided copper tape then sputter coated with gold 
for one min under vacuum at 0.05 mbar by a sputter coater (High Resolution Sputter 
Coater 208HR, Cressington Scientific, Watford, UK). The SEM was operated at an 
accelerating voltage of 2-5 kV. 
Particle size distributions and mean particle diameters were measured by static light 
scattering on a Malvern Mastersizer 2000 with the Scirocco dry dispersion unit (Malvern 
Instruments Ltd, Malvern, UK). Analysis was conducted based on the refractive index of 
CS (1.681) and BDP (1.564). Samples were added at a feed pressure of 3.5 bar for 
cromolyn sodium (CS) formulations and 2.0 bar for beclomethasone dipropionate (BDP) 
formulations. Each experiment was conducted in triplicate at ambient temperature.  
The aerosol performance of the spray-dried powders was assessed using a multi-stage 
liquid impinger (MSLI, Copley Scientific, Nottingham, UK) coupled with a United States 
Pharmacopoeia (USP) stainless steel throat in a walk-in environmental chamber 
(Synersys, Singapore) maintained at 25 °C and 40% RH. Prior to testing, 20 mL of 
deionised water (for CS formulations) or methanol-water (3:1 v/v) (for BDP 
formulations) was added across all four stages of the MSLI. Powder from each 
formulation was filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3, 
Capsugel®, Morristown, NJ, USA), loaded into the high-efficiency Aerolizer® inhaler 
(Novartis Pharmaceuticals, Basel, Switzerland) and pierced. The powder was then 
2.5 Powder morphology 
2.6 Particle size analysis 
2.7 In vitro aerosol performance 
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dispersed for 4 s at 60 L/min. The flow through the MSLI was measured with a calibrated 
flow meter (TSI Model 4040C, TSI Instrument Ltd., Buckinghamshire, UK), controlled 
by a critical flow controller (TPK 2000, Copley Scientific, Nottingham, UK) and a dry-
running rotary vane vacuum pump (Seco SV 1040 C, Busch LLC, Virginia Beach, VA, 
USA). The test was performed in triplicate to obtain mean values.  
After dispersion, the device, capsule, throat and each stage of the MSLI were washed 
separately and thoroughly using deionised water (for CS formulations) or methanol-water 
(3:1 v/v) (for BDP formulations). Drug deposited at different locations was assayed by 
UV spectrophotometry (Cary 50 Conc UV-visible spectrophotometer, Varian Inc., Palo 
Alto, CA, USA) or HPLC (1100 series; Agilent Technologies, Santa Clara, CA, USA). 
In this study, fine particle fraction (FPF) represents the mass fraction of drug particles 
smaller than 5 µm in the aerosol cloud relative to the total mass recovered and was 
obtained by interpolation to the cumulative percent undersize at 5 µm. FPF (emitted) was 
obtained when the fine particle dose was expressed relative to the emitted dose. At a flow 
rate of 60 L/min, the aerodynamic cut-off diameters of stages 1, 2, 3 and 4 are 13.0, 6.8, 
3.1 and 1.7 µm. Particles with diameters less than 1.7 µm were captured on an integral 
glass fibre filter paper. 
There are several models which can describe drug dissolution from pharmaceutical 
dosage forms. The type of drug, its crystallinity, particle size distribution, solubility, 
polymorphic form of drug, and drug loading can all affect the release kinetics (Ei-Arini 
and Leuenberger, (1995)). The dissolution profiles of the formulations were analysed by 
various established mathematical kinetic models in literature (Costa and Sousa Lobo, 
(2001)) and described further below.  
Pharaceutical dosage forms that do not disaggregate and release the drug slowly can be 
described the zero order kinetics. It has the ideal profile of the same quantity of drug 
release per unit time.  
 
Zero order kinetics:   
 𝑓𝑡 = 𝐾0𝑡 (12) 
2.8 Mathematical models of dissolution profiles 
2.8.1 Zero order kinetics 
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where ft represents the fraction of drug dissolved at time and K0 the rate constant for zero 
order release 
First order kinetics describe pharmaceutical dosage forms whereby the drug release is 
proportional to the amount of drug remaining. The amount of drug release per unit time 
decreases over time. This model assumes that the matrix is insoluble, does not swell, and 
is inert to the drug. The release of water-soluble drugs from a porous matrix will follow 
such a dissolution profile. 
 
First order kinetics:   
 ln 𝑄𝑡 = −𝐾1𝑡 + ln𝑄0 (13) 
 
where Qt is the amount of drug dissolved at time t, Q0 is the initial amount of drug in 
solution, and K1 is the rate constant for first order release. 
The Hixson-Crowell model (Hixson and Crowell, (1931)) describe the situation where 
the dosage form’s geometric shape diminish proportionately over time. In this case, the 
assumption is that the rate-limiting step is the drug particle’s dissolution rate, rather than 
diffusion rate through a polymeric matrix.  
 
Hixon-Crowell model:   
 (1 − 𝑓𝑡)
1 3⁄ = 1 − 𝐾𝛽𝑡 (14) 
 
where ft represents the fraction of drug dissolved at time, and Kβ is the rate constant for 
the Hixson-Crowell model. 
The Higuchi model bases itself on Fick’s first law (Higuchi, (1963), (1961)), and 
describes drug release as a diffusion process which is square root time dependent. In 
contrast to the Hixson-Crowell model, the rate-limiting step for the Higcuhi model is the 
2.8.2 First order kinetics 
2.8.3 Hixson-Crowell model 
2.8.4 Higuchi model 
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diffusion rate, rather than a drug particle’s dissolution rate. It can be used to describe 
systems such as water-soluble drugs in a tablet matrix.  
 
Higuchi model:   
 𝑓𝑡 = 𝐾𝐻𝑡
1 2⁄  (15) 
 
where ft represents the fraction of drug dissolved at time, and KH is the rate constant for 
the Higuchi model. 
The Baker-Lonsdale model was derived from the Higuchi model for drug release from a 
spherical matrix (Baker and Lonsdale, (1974)). Drug particles are assumed to be small 
relative to matrix radius, and the matrix is assumed to be non-swelling and non-erodible. 
 
Baker-Lonsdale model:   
 𝑓𝑡 =
3
2
[1 − (1 −
𝑀𝑡
𝑀∞
)
2 3⁄
] −
𝑀𝑡
𝑀∞
=
3𝐷𝑚𝐶𝑚𝑠
𝑟0
2𝐶0
𝑡 = 𝑘𝑡 (16) 
 
where ft represents the fraction of drug dissolved at time, Mt is the amount of drug released 
at time t, M∞ is the amount of drug released at infinite time, Dm is the diffusion coefficient, 
Cms is the drug solubility in the matrix, r0 is the radius of the spherical particle matrix, C0 
is the initial concentration of drug in the matrix, and k is the slope of the linear Baker-
Lonsdale model plot.  
The Korsmeyer-Peppas model (Korsmeyer et al., (1983)) is a semi-empirical model 
where drug release is related to the time exponentially. The release exponent accounts for 
different types of drug transport mechanisms (Fickian, anomalous, Case-II, Super Case-
II), and can be used to describe pharmaceutical dosage forms where the release 
mechanism is not well known or complex (more than a single type of release mechanism 
involved).  
 
Korsmeyer-Peppas model:   
2.8.5 Baker-Lonsdale model 
2.8.6 Korsmeyer-Peppas model 
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 log𝑀𝑡 = 𝑛 ∙ log𝑡 + log(𝑎 ∙ 𝑀∞) (17) 
 
where Mt is the amount of drug released at time t, M∞ is the amount of drug released at 
infinite time, n is the release exponent related to the drug release mechanism, a is a 
constant incorporating structural and geometrical aspects of the drug particles. 
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The potential advantages of administering medication by inhalation are well known to us 
(Bryan, (1930)); for respiratory related diseases, therapeutics can be delivered with a 
rapid onset of action directly to the ailment site in the lung and has the advantage of 
avoiding hepatic first pass metabolism in the process. The required amount of dose can 
be decreased with localised delivery to the lung and side effects usually associated with 
systemic delivery may be minimised (McCalden, (1990); Olsson et al., (2011)). Recently, 
delivery through the lungs has also been mooted as an attractive non-invasive route for 
delivery of drugs into systemic circulation (Patton and Byron, (2007)) as the lung presents 
a large surface area for absorption with only a thin barrier to absorption. 
However, pulmonary drug delivery systems are limited by the effective clearance systems 
in the lung. Water-soluble drugs are often quickly absorbed upon administration and may 
3 HYBRID PROTEIN-POLYMER 
PARTICLES FOR RELEASE 
MODULATION OF INHALED 
POWDERS 
3.1 Introduction 
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experience uncomfortable peaks in local concentrations, followed by lower than 
therapeutic level concentrations (Loira-Pastoriza et al., (2014)). Sustaining the release of 
drugs may reduce the need for frequent dosing, leading to greater patient convenience 
and compliance. 
Particle engineering plays an important part in the development of controlled inhalation 
therapy strategies, particularly for dry powder inhalers (DPIs) (Chow et al., (2007); 
Hickey and Mansour, (2008)). Particles in the nanometre range are predominantly 
exhaled from the lungs, while large particles will be trapped in the oropharynx for 
clearance via the mucociliary escalator (Grenha et al., (2007)). Hence, to be viable, any 
controlled release system should efficiently produce particles with a mass median 
aerodynamic particle (MMAD) size of 1-5 μm (Labiris and Dolovich, (2003); Patton and 
Byron, (2007)). Controlling the release of water-soluble drugs in the lungs has an 
additional conundrum in that small particles are required for delivery to the lower 
airways, but a high surface area-to-mass ratio simultaneously favours a more rapid 
release. DPIs are also governed largely by particle properties such as particle size (Chew 
and Chan, (1999); Zeng et al., (2000)), particle size distribution (Chew and Chan, (2002)), 
density (D’Addio et al., (2012)), morphology (Adi et al., (2008); Berkenfeld et al., 
(2015); Chan, (2008); Chew et al., (2005); Dunbar et al., (1998)), and electrostatic forces 
(Chow et al., (2008); Kwek et al., (2013); Zhu et al., (2008), (2007)). 
Polymeric microparticles have been widely adopted to control the release of drugs for 
oral delivery and can easily be prepared by established manufacturing techniques. Much 
research on the ability of polymeric particles to control the release of drugs in the lung 
has been conducted (Learoyd et al., (2008); Möbus et al., (2012); Saigal et al., (2013); R. 
O. Salama et al., (2009b)).  
However, there is an inherent difficulty in controlling the release of water-soluble drugs 
due to the size constraints required to deliver particles to the lower airways, given that 
increasing the size of the particles is one of the most commonly adopted strategies for 
controlling the release of a drug.  
Poly(vinyl alcohol) (PVA) is a well-established polymer for biomedical applications as a 
drug carrier (Gul et al., (2009); Mallapragada and McCarthy-Schroeder, (2000)). PVA 
has been used for controlling the release of therapeutic agents in the lung (Haghi et al., 
(2012); Saigal et al., (2013); R. Salama et al., (2008); R. O. Salama et al., (2009a), 
(2009b), (2008)) after it was found that 1% (w/w) of PVA could affect the pulmonary 
absorption significantly (Yamamoto et al., (2004)). In 2009, Salama et al. studied the 
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controlled release of BSA from PVA microparticles. They found that they were able to 
delay the release of BSA by up to 12 times with the addition of 90% (w/w) PVA. 
Furthermore, the authors were able to display that PVA was not toxic to human alveolar 
basal epithelium cells, A549, in vitro. However, as effective as PVA is in delaying the 
release of therapeutic agents, its long-term effects are still largely unknown (Nakamura 
et al., (2001); Sheth and Myrdal, (2011b)).  
Albumin is the most abundant blood protein in humans.  Albumins have been used as a 
natural polymer for drug delivery since first described by Kramer in 1974, but have been 
receiving increased attention in recent years as a versatile drug carrier (Elsadek and Kratz, 
(2012); Kratz, (2008); Park, (2012)). Certain properties that make albumins such an 
attractive drug carrier include its biodegradability, non-toxicity and non-immunogenicity 
(Kratz, (2008)). Intravenous albumin-bound paclitaxel (Abraxane) has been approved by 
the United States Food and Drug Administration (US FDA) for use in the treatment of 
non-small-cell lung cancer (Green et al., (2006)), although the use of albumin for 
pulmonary drug delivery has seen far less research and development. As serum albumins 
are present in pulmonary surfactant (Whitsett and Weaver, (1991)) and are also found in 
large quantities in lung epithelial fluid, coupled with the aforementioned qualities, they 
have potential for use in pulmonary delivery systems. Li et al. have developed bovine 
serum albumin (BSA) microspheres to deliver ciprofloxacin as a dry powder to the lung 
and cross-linked BSA has been found to be beneficial in controlling the release of 
terbutaline sulphate (Sahin et al., (2002)). The use of albumin nanoparticles for drug 
delivery to the lung has recently been explored by (Woods et al., (2015), (2014), (2013)) 
where albumin nanoparticles were shown to be an attractive candidate for controlling the 
release of drugs in the lung in vivo and were also demonstrated to be largely degraded by 
48 hours. The addition of proteins (e.g. albumins like BSA) to pulmonary delivery 
systems has also been suggested to be beneficial in enhancing the aerosol performance of 
such systems by inducing corrugation (Bosquillon et al., (2001); Chew and Chan, (2001)).  
Cromolyn sodium (CS), also known as sodium cromoglycate or cromoglicic acid, is an 
anti-allergic drug used in the treatment of asthma. However, it requires administration 
four times daily by metered dose inhaler or nebuliser, making it inconvenient for the 
patient (Fanta, (2009)). Vidgren et al., 1987 first attempted to spray-dry CS for inhalation 
therapy in 1987, producing particles that were smaller in size and had a better impaction 
test performance than their micronised counterparts. CS is a highly water-soluble drug, 
so producing and retaining it in its amorphous form is not necessary, but control of 
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particle size and surface properties, as well as its release rate,  are desirable. 
In this work, we describe a spray-dried hybrid protein/polymer microparticle pulmonary 
drug delivery carrier system comprising two excipients with complementary attributes - 
a protein which has been found to improve aerosol performance, BSA; and a polymer 
known to control the release of therapeutic agents in the lung, PVA - to deliver an anti-
asthma drug, CS. The unique drug delivery system seeks to complement the sustained 
release characteristics of PVA with the aerosol dispersibility of BSA. A factorial design 
approach was adopted to study the behaviour of this hybrid system, investigating the 
influence of drug loading and protein/polymer ratio to the physicochemical properties of 
the formulation, in particular, the drug release profiles and the deposition studies. It is 
hoped that with the detailed study of the physicochemical characteristics of the hybrid 
formulation, the feasibility of employing two excipients, each with a specific purpose, to 
obtain an optimised formulation combining the advantages of both excipients, can be 
investigated. 
CS was supplied by Sanofi-Aventis (Paris, France) while PVA (MW 88,000) was 
supplied by Tokyo Chemical Industry Co. Ltd (Tokyo, Japan). BSA was procured from 
Sigma-Aldrich (St. Louis, MO, USA). Potassium dihydrogen phosphate (Alfa-Aesar, 
Ward Hill, MA, USA) and sodium hydroxide (Merck KGaA, Darmstadt, Germany) were 
used to make pH 7.4 phosphate buffer solution (PBS). All water used throughout was 
purified via reverse osmosis by an ELGA PURELAB Option-Q (Veolia Water, Paris, 
France) purification system. 
Using a 3 x 2 factorial design where two variables (drug loading and protein/polymer 
ratio) have three levels each, a range of microparticles with 20, 50 and 80% (w/w) CS 
loadings, and protein/polymer ratios of 1:1, 4:1 and 1:4 (by weight) were prepared from 
aqueous solutions as detailed in Table 3.1. 
Typically, varying amounts of the active ingredient were measured out and dissolved in 
3.2 Materials and Methods 
3.2.1 Materials 
3.2.2 Methods 
3.2.2.1 Microparticle preparation via co-spray drying 
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deionised water before the dispersion of corresponding amounts of carrier materials. The 
spray drying was performed on a laboratory scale spray dryer equipped with a high 
performance separating cyclone and 0.7 mm nozzle (B-290 Mini Spray Dryer, BÜCHI 
Labortechnik AG, Flawil, Switzerland). The mini spray dryer was operated in an ‘open 
loop’ configuration for aqueous solutions with the following conditions: Inlet temperature 
140 °C, outlet temperature ~70 °C, aspirator gas flow rate 35 m3/h, atomising spray air 
flow rate 601 L/h and solution feed rate at 5 mL/min. All spray-dried powders were dried 
overnight in a vacuum oven (Heraeus Vacutherm VT 6060M, Thermo Electron 
Corporation, Waltham, MA, USA) set at 25 °C after collection. 
The thermal profiles of the powders were determined by differential scanning calorimetry 
(DSC) and modulated differential scanning calorimetry (MDSC). Experiments were 
conducted on a TA Instruments Q2000 Differential Scanning Calorimeter (New Castle, 
DE, USA). Approximately 3-5 mg of powder was placed into a Tzero® aluminium pan 
and a lid was crimped on. An empty pan was used as reference. Measurements were taken 
in DSC mode with a heating rate of 10 °C/min, and in modulation mode with a heating 
rate of 5 °C/min, and modulation of ± 0.5 °C every 100s. Glass transition temperatures 
(Tg) were determined by analysing the reversing heat flow signal. 
The microparticles’ microstructure was probed by focused ion beam (FIB) milling using 
a focused ion beam/scanning electron microscope dual beam system (FEI Nova NanoLab 
200, FEI Company, Hillsboro, OR, USA  & Zeiss CrossBeam 1540, Carl Zeiss 
Microscopy GmbH, Jena, Germany ). The accelerating voltage and beam current were 
adjusted to accommodate the fragility of each formulation and were approximately 30 kV 
and 100-500 pA respectively. The powders were mounted onto double-sided adhesive 
copper tape and coated with platinum. The samples were examined under high-resolution 
FESEM at 2-5 kV. 
 
 
3.2.2.2 Thermal analysis 
3.2.2.3 Particle microstructure 
3.2.2.4 Density and aerodynamic diameter 
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Pycnometry on the samples was performed using a helium pycnometer (AccuPyc 1330, 
Micromeritics Instrument Corporation, Norcross, GA, USA) equipped with a 3.5 cm3 
insert. The typical mass used was between 0.5 g to 1 g, with the values quoted being the 
mean and standard deviation from a cycle of 10 measurements. 
The aerodynamic diameter was calculated using Equation 2 in Section 1.1.2. 
The release studies of the prepared microparticles were assessed by two different 
methodologies – United States Pharmacopoeia (USP) dissolution apparatus 1 (basket 
apparatus) and the USP dissolution apparatus 4 (flow-through cell). Prior to the 
dissolution studies, assays of each prepared formulation were conducted whereby a 
measured quantity of powder was dissolved in pH 7.4 PBS for 24 hours before a 
spectrophotometric analysis of the dissolved drug concentration was conducted to 
determine the amount of drug loading. 
The dissolution profile of CS was measured using a United States Pharmacopoeia (USP) 
dissolution apparatus 1 (basket apparatus) (Varian VK 7010 Dissolution Apparatus, 
Varian Inc., Palo Alto, CA, USA) with online flow cell (Cary 50 Conc UV-visible 
spectrophotometer, Varian Inc., Palo Alto, CA, USA). The basket rotation speed was set 
at 50 RPM and the vessel temperature at 37 °C. Typically, 40 mg of spray-dried aerosol 
powders and 20 mg of spray-dried pure CS was used for dissolution studies in 900 mL of 
pH 7.4 PBS. Samples were taken by the auto sampling system at five-minute intervals, 
after which the samples were returned to the dissolution vessel by a peristaltic pump. UV 
readings were taken at 326 nm. 
A USP dissolution apparatus 4 (flow-through cell) (DFZ 720 flow-through-cell 
dissolution tester, Erweka GmbH, Heusenstamm, Germany) was used in the ‘closed-loop’ 
configuration to conduct release studies of CS. The temperature of the water baths 
surrounding the cells were maintained at 37 °C. 900 mL of dissolution media was 
maintained at 37 °C before being pumped through the system using a peristaltic pump 
(IPC 8 microprocessor-controlled dispensing pump, Ismatec SA, IDEX Health & Science 
3.2.2.5 In vitro dissolution studies 
3.2.2.5.1 USP dissolution apparatus 1 (basket apparatus) 
3.2.2.5.2 USP dissolution apparatus 4 (flow-through cell) 
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GmbH, Wertheim, Germany) at a constant flow rate of 0.5 mL/min. 25-100 mg of spray-
dried aerosol powders or 20 mg of spray-dried pure CS were used for dissolution studies. 
As seen in Figure 3.1, the powders were sandwiched between 1 mm glass beads (to 
promote laminar flow), which were bounded by 0.45 µm PTFE filters. The area exposed 
to vertical flow was 1.25 cm in diameter and dissolution medium exiting the flow-through 
cell was returned to the 900 mL dissolution medium. At pre-determined time intervals, 3 
mL aliquots were collected from the dissolution medium for analysis with the UV-vis 
spectrophotometer. 
 
Figure 3.1. Schematic of Erweka DFZ 720 USP dissolution apparatus 4 (flow-through 
cell) in ‘closed loop’ configuration. 
The concentrations of CS in the prepared powders were analysed spectrophotometrically 
(Cary 50 Conc UV-visible spectrophotometer, Varian Inc., Palo Alto, CA, USA) at a 
wavelength of 326 nm. All samples and standards were prepared in pH 7.4 PBS. The 
standards showed a good linear fit by least squares linear regression (Figure 3.2.). The 
addition of BSA (wavelength 280 nm) and PVA to CS did not interfere with the UV 
3.2.2.6 Spectrophotometric study of CS 
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spectrum. 
 
Figure 3.2. Relationship between CS concentration and UV absorbance.  
Analysis was performed to investigate the effect of drug loading and protein/polymer 
ratio on the physicochemical characteristics of the formulations. The design of 
experiments was based on a 3 x 2 factorial design, with three levels for the two variables 
(Table 3.1). 
The spray-drying yield, experimental drug loading and entrapment efficiency of each 
spray-dried formulation is shown in Table 3.1. Spray-dried CS and CS/BSA-50/50- SD 
both achieved high yields of > 80% (w/w) compared to the typical yield of 50-70% for 
spray-dried inhalable particles (“Laboratory scale spray drying Of inhalable drugs: A 
review,” (2010)). The yield dropped drastically to 27% for CS/PVA-50/50-SD. For the 
hybrid formulations, a clear trend can be seen where the formulations with a greater 
BSA/PVA ratio had higher yields. A possible reason for the low yields for the 
3.3 Results and discussion 
3.3.1 Yield, drug loading, and entrapment efficiency 
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formulations with PVA is that the outlet temperature of ~70 °C was too close to the ‘sticky 
point’ of PVA (Maury et al., (2005)), which is estimated to be approximately ~10-20 °C 
above a substance’s Tg, which for PVA would be ~95 °C, given its Tg of 85 °C 
(Mallapragada et al., (1996)), causing the spray particles to stick to the walls of the drying 
chamber and separating cyclone. 
The experimental drug loadings of all the formulations were close to their theoretical 
values and the minimum entrapment efficiency was ~90%, which showed that spray-
drying was indeed a viable process to form drug-loaded hybrid particles. 
 
Table 3.1. Spray-drying Yield, Drug Loadings, Entrapment Efficiency and 
Protein/Polymer Ratios of CS/BSA/PVA Microparticle Formulations. SD Denotes Spray-
Investigating Controlled Release Pulmonary Drug Delivery Systems 
46  Leonard Chia - February 2018 
dried. 
No. Name 
Spray-
drying 
Yield 
(%) 
Theoretical 
Drug 
Loading 
(% w/w) 
Experimental 
Drug 
Loading (% 
w/w) 
Entrapment 
Efficiency 
(%) 
BSA/PVA 
0 CS-raw - - - -  
1 CS-SD 81.28 - - - 1:0 
2 
CS/BSA-
50/50-SD 
88.35 50 47.27 94.53 0:1 
3 
CS/PVA-
50/50-SD 
27.05 50 45.06 90.12 4:1 
4 
CS/BSA/PVA-
20/64/16-SD 
67.80 20 19.78 98.89 4:1 
5 
CS/BSA/PVA-
50/40/10-SD 
67.75 50 44.80 89.61 4:1 
6 
CS/BSA/PVA-
80/16/4-SD 
57.92 80 73.55 91.94 4:1 
7 
CS/BSA/PVA-
20/10/10-SD 
46.62 20 18.81 94.04 1:1 
8 
CS/BSA/PVA-
50/25/25-SD 
52.60 50 45.31 90.62 1:1 
9 
CS/BSA/PVA-
80/10/10-SD 
52.45 80 71.87 89.83 1:1 
10 
CS/BSA/PVA-
20/4/16-SD 
37.03 20 19.50 97.48 1:4 
11 
CS/BSA/PVA-
50/10/40-SD 
35.90 50 46.89 93.78 1:4 
12 
CS/BSA/PVA-
80/4/16-SD 
36.04 80 81.31 101.63 1:4 
 
Figure 3.3 displays the X-ray diffractograms of the raw CS drug and the spray-dried 
3.3.2 Powder crystallinity 
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formulations with varying amounts of BSA and PVA. The results indicate that the spray-
dried formulations were all in the amorphous state after spray drying. 
 
Figure 3.3. X-ray diffractograms of crystalline raw CS and amorphous co-spray dried 
formulations based on a 3 x 2 factorial design. 
The Tg of CS has hitherto not been reported as it overlaps with the large solvent 
evaporation endotherm (Najafabadi et al., (2004); Nolan et al., (2011)). Using MDSC, 
we were able to separate the heat flow into its heat capacity (reversing heat flow) and 
kinetic (non-reversing heat flow) components. Upon investigation of the reversing heat 
flow component of the MDSC thermogram of spray-dried CS in Table 3.3, the Tg of CS 
was determined to onset at approximately 58 °C. 
3.3.3 Thermal analysis 
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Figure 3.4. MDSC thermogram of CS-SD with inset of the glass transition. Total heat 
flow represented with (• • • •), non-reversing heat flow with (▬ ▬), and reversing heat 
flow with (▬▬). 
Analysis of the MDSC thermograms of the spray-dried formulations revealed that at least 
two disparate thermal transitions were observed. The first of which typically occurs at 
approximately 40 °C for all formulations. This transition has the appearance of a glass 
transition but has been postulated by Mizuno and Pikal, (2013) to be a protein internal 
transition related to α-mobility. The second transition occurs at approximately that of 
PVA at 85 °C.  
The equilibrium moisture sorption isotherms of the spray-dried formulations are shown 
in Figure 3.5. Spray-dried CS had the highest moisture sorption with 48.81% mass change 
at 90% RH, while CS/BSA-50/50-SD and CS/PVA-50/50-SD had 42.41% mass change 
and 38.53% mass change at 90% RH, respectively. Formulations with 20% drug loading 
are shown with  markers, in shades of red; formulations with 50% drug loading are 
shown with  markers, in shades of blue; and formulations with 80% drug loading are 
shown with  markers, in shades of green. There was no evidence of moisture-induced 
crystallisation. As can clearly be seen in Figure 3.5, the formulations had similar sorption 
isotherms when they had the same drug loading, with the moisture sorption decreasing 
slightly when the protein/polymer ratio went from 4:1 to 1:1 to 1:4 (w/w). Drug loading, 
3.3.4 Moisture sorption 
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however, appeared to have the larger influence on the amount of moisture sorption with 
formulations of 20% drug loading having the lowest equilibrium moisture sorption, while 
formulations with 80% drug loading had sorption isotherms similar to that of spray-dried 
CS.  
 
Figure 3.5. DVS sorption isotherms of spray-dried formulations. 
As water is a very powerful plasticiser, the amount of moisture absorbed is important in 
deciding the storage conditions of the drug formulations. However, from the perspective 
of dissolution performance, as CS is a highly water-soluble compound, its crystallisation 
from an amorphous, spray-dried state is arguably of less importance than that of a poorly 
water-soluble drug compound which would benefit greatly from the dissolution rate 
enhancement of its amorphous form. On the other hand, moisture absorption was found 
to have a deleterious effect on the aerosol performance of CS powders (Li et al., (2016)) 
which could be due to re-crystallisation increasing the size of the particles to beyond that 
of the respirable range, so appropriate packaging, such as sealed blister packs, should be 
considered when packaging these powders. 
The surface composition of the raw and spray-dried drug, protein, polymer and hybrid 
formulations were estimated from XPS peaks and shown in Table 3.2. The raw and spray-
dried forms of CS and BSA did not differ much in their experimentally derived surface 
3.3.5 Surface composition estimation 
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composition while there was a slight change in the composition of spray-dried PVA 
compared to its raw counterpart. 
 
Table 3.2. Surface Composition (Atomic %) of Raw and Spray-dried CS, BSA, PVA. 
Sample Carbon (%) Oxygen (%) Nitrogen (%) Sodium (%) 
CS-raw 72.28 24.3 - 2.92 
CS-SD 73.18 24.13 - 2.68 
BSA-raw 71.64 15.52 12.84 - 
BSA-SD 70.55 15.53 13.92 - 
PVA-raw 76.79 23.21 - - 
PVA-SD 72.7 27.3 - - 
 
In Table 3.3, the estimated surface coverage of the spray-dried hybrid formulations can 
be seen. It is clear that there is little to no CS on the surface of the particles and that the 
surface coverage of the hybrid particles was dominated by the excipients, BSA and PVA. 
This relationship can be seen more clearly in Figure 3.6. In concentrations greater than 
25% (w/w) in the feed solution, PVA completely dominated the surface. This did not 
appear to have a beneficial or detrimental effect based on the characterisation tests 
performed, but this effect could possibly be harnessed in coating the drug in with a 
protective (e.g. moisture-protective) compound. 
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Table 3.3. Estimated Surface Coverage (Wt %) of Spray-dried Hybrid Formulations. 
Formulation CS-SD (%) BSA-SD (%) PVA-SD (%) 
2 0.03 99.97 - 
3 -0.14 - 100.14 
4 0.03 2.26 97.71 
5 0.11 7.54 92.35 
6 0.24 32.08 67.68 
7 0.04 0.64 99.32 
8 -0.06 -0.94 101.00 
9 0.79 12.51 86.70 
10 0.11 1.76 98.13 
11 -0.06 -0.95 101.02 
12 0.40 6.25 93.35 
 
 
Figure 3.6. Relationship between surface coverage of BSA () and PVA () and the 
concentration of PVA in the feed solution. 
Figure 3.7 shows spherical particles of CS/BSA/PVA formed after spray-drying as well 
as the plate-shaped particles of raw CS [Figure 3.7-(0)]. The images are broadly in 
agreement with particle size distribution data shown later in Table 3.4. Spray-dried 
3.3.6 Particle morphology 
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CS/BSA-50/50-SD [Figure 3.7-(2)] was seen to comprise of small particles with 
corrugated surfaces while spray-dried CS/PVA-50/50-SD [Figure 3.7-(3)] displayed 
larger particles with smooth surfaces. 
The effect of drug loading on the particles can be seen for different protein/polymer ratios. 
Figure 3.7-(4), Figure 3.7-(5) and Figure 3.7-(6) show particles with a protein/polymer 
ratio of 4:1; Figure 3.7-(7), Figure 3.7-(8) and Figure 3.7-(9) show particles with a 
protein/polymer ratio of 1:1; Figure 3.7-(10), Figure 3.7-(11) and Figure 3.7-(12) show 
particles with a protein/polymer ratio of 1:4. At all three protein/polymer ratios, it can be 
seen that for increasing drug loading, the particles’ surface corrugation appeared to 
progressively increase toward that seen for spray-dried CS in Figure 3.7-(1). The surface 
corrugation has been suggested to improve the aerosol dispersibility of the formulations 
(Bosquillon et al., (2001); Chew and Chan, (2001)). 
Similarly, when observing the particles for the effect of protein/polymer ratio; Figure 3.7-
(4), Figure 3.7-(7) and Figure 3.7-(10) for 20% (w/w) drug-loaded particles; Figure 3.7-
(5), Figure 3.7-(8) and Figure 3.7-(11) for 50% (w/w) drug-loaded particles; Figure 3.7-
(6), Figure 3.7-(9) and Figure 3.7-(12) for 80% (w/w) drug-loaded particles, the surface 
roughness of the particles appeared to increase with increasing protein/polymer ratio, 
towards that of CS/BSA-50/50-SD [Figure 3.7-(2)] although not to the same extent as 
seen for increasing drug loading. It can also be observed that increasing the 
protein/polymer ratio yielded a greater amount of small particles, with Formulation 4, 
CS/BSA/PVA-20/64/16-SD in Figure 3.7-(4), in particular, displaying a high amount of 
small particles. 
The particle size distribution of the microparticles observed in the SEM micrographs was 
in good agreement with the laser diffraction data seen later in Section 3.3.8. Smaller 
particles were produced when the drug loading was low, with a high protein/polymer 
ratio. It was also noted that when more polymer was included in the carrier composition 
(1:4 (w/w) protein/polymer ratio: [Figure 3.7-(10), Figure 3.7-(11) and Figure 3.7-(12)]), 
the surfaces appeared smoother and there was an increased aggregation tendency. 
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Figure 3.7. Scanning electron micrographs of formulations 0-12. Scale bars (in red) are 1 
µm for all images except for (0) CS-raw, for which it is 10 µm. 
Images of FIB-milled microparticles can be seen in Figure 3.8. Both CS-SD [agreeing 
with data from (Heng et al., (2007))] and CS/BSA-50/50-SD comprised of solid particles, 
3.3.7 Microparticle microstructure 
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while CS/PVA-50/50-SD exhibited a slightly hollow interior. Most of the hybrid 
formulations, however, were hollow with only CS/BSA/PVA-20/64/16-SD and 
CS/BSA/PVA-20/40/40-SD having solid interiors, suggesting that a low percentage of 
CS and a high percentage of BSA created conditions for the formation of solid particles. 
Interestingly, when two formulations with a similar median particle size, Formulation 6 
– CS/BSA/PVA-80/16/4-SD and Formulation 7 – CS/BSA/PVA-20/40/40-SD, but with 
a different microstructure – Formulation 6 had hollow particles whilst Formulation 7 had 
solid particles – were studied, the FPF of Formulation 6 with the hollow particles was 
less than that of Formulation 7 with solid particles. As will be investigated further later, 
while the formulations may have a similar geometric median particle size (4.68 µm vs 
4.77 µm), their aerodynamic diameters were quite different (9.99 µm vs 5.15 µm) with 
corresponding FPFs of 22.1% and 30.5%, due to the difference in their densities, implying 
that although the particle microstructure directly affects its density, solid particles with 
inherently lower densities may have a greater effect on the aerosol performance of the 
powders.  
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Figure 3.8. Secondary electron images of the FIB cross-sections of the spray-dried 
formulations. 
As mentioned earlier, the particle size distribution of a formulation is an important factor 
in the viability of any pulmonary delivery system in order to circumvent the clearance 
mechanisms of the respiratory system. The particle size of the formulations affect most 
of the other physicochemical characteristics of the formulations and are integral to the 
performance of the formulations. The particle size distributions of the formulations are 
3.3.8 Particle size analysis 
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shown in Table 3.4. From Table 3.4, we can observe that the bulk of the formulations had 
median particle sizes within the respirable range.  
 
Table 3.4. Volume Particle Size Distributions of Spray-dried Formulations. 
Formulation d10 (µm) d50 (µm) d90 (µm) Span (µm) 
0 1.11 ± 0.03 2.24 ± 0.05 4.61 ± 0.18 1.56 
1 1.15 ± 0.06 2.68 ± 0.03 5.71 ± 0.18 1.70 
2 1.27 ± 0.02 2.69 ± 0.04 5.41 ± 0.21 1.54 
3 2.99 ± 0.03 10.51 ± 0.18 32.06 ± 3.12 2.76 
4 1.06 ± 0.03 2.99 ± 0.06 8.18 ± 0.11 2.38 
5 1.40 ± 0.01 4.24 ± 0.07 12.40 ± 1.25 2.59 
6 1.59 ± 0.08 4.68 ± 0.26 11.31 ± 0.30 2.08 
7 1.48 ± 0.00 4.77 ± 0.10 13.29 ± 0.15 2.48 
8 1.61 ± 0.05 5.83 ± 0.03 18.10 ± 1.52 2.83 
9 1.94 ± 0.15 5.71 ± 0.34 14.56 ± 1.57 2.21 
10 2.34 ± 0.04 8.13 ± 0.15 20.80 ± 0.32 2.27 
11 2.42 ± 0.03 8.24 ± 0.31 24.33 ± 3.07 2.66 
12 2.45 ± 0.19 8.00 ± 0.33 21.08 ± 0.43 2.33 
 
In Figure 3.9, the effect of drug loading on the particle size distribution of the 
formulations was studied. It was observed that the effect of drug loading on the median 
particle size of the formulations decreased as the protein/polymer ratio went from 4:1 to 
1:1 to 1:4 (w/w). Although spray-dried CS had a small particle size (2.68 µm), it did not 
appear to have had a great influence on reducing the particle size of the formulation and 
the protein/polymer ratio seemed to have had a far greater effect. 
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Figure 3.9. Effect of drug loading on median particle size. 
The effect of protein/polymer ratio of the formulations was compared in Figure 3.10. At 
all drug loadings, it can clearly be seen that the median particle size of the hybrid 
formulations fell as the protein/polymer ratio was increased. Spray-dried PVA has been 
found to be hollow, thereby increasing its particle size (Ting et al., (1992)). When the 
particles were split using FIB (Figure 3.8), it was observed that while CS-SD and 
CS/BSA-50/50-SD were small solid particles, there existed hollow particles in most of 
the other formulations, possibly contributing to the larger particle sizes. 
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Figure 3.10. Effect of protein/polymer ratio on median particle size. 
The densities of spray-dried CS and the hybrid formulations were measured by helium 
pcynometry and are shown in Table 3.5 alongside the estimated proportional density, 
median particle size, calculated aerodynamic diameter (dae), the percentage of dae < 5 µm, 
and the FPF (discussed in Section 3.3.10). The density of spray-dried CS was 
approximately 1.58 g/cm3 and agreed with data previously reported (Cox et al., (1971)). 
From Figure 3.11, it can be seen that the specific density of the formulations rose when 
drug loading was increased for all protein/polymer ratios while the specific density 
decreased when the protein/polymer ratio was increased (Figure 3.12). It is worthwhile 
to note that at 80% (w/w) drug loading, the specific density only decreased to 
approximately that of spray-dried CS, while at lower drug loadings, increasing the 
protein/polymer ratio was able to reduce the specific density to approach that of spray-
dried CS/BSA-50/50-SD (1.43 g/cm3). 
 
 
3.3.9 Density and aerodynamic diameter 
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Table 3.5. Specific Density Measurements and Estimations, Aerodynamic Diameter Calculations, and Deposition Parameters (Mean ± SD, n=3) of 
Formulations Measured by MSLI. 
Formulation 
Density 
(g/cm3) 
Standard 
Dev. 
(g/cm3) 
Estimated 
Proportional 
Density (g/ cm3) 
d50 
(µm) 
dae 
(µm) 
dae < 5 µm  
(%) 
FPF (%) FPF 
(emitted) 
(%) 
0 1.65 0.0019 - 2.24 - - 5.6 ± 0.2 5.9 ± 0.2 
BSA-SD 1.32 0.0008 -  - - - - 
PVA-SD 1.66 0.0036 -  - - - - 
1 1.58 0.0018 - 2.68 3.37 74.0 28.0 ± 2.1 37.4 ± 3.3 
2 1.43 0.0010 1.45 2.69 3.21 78.0 50.2 ± 2.9 57.3 ± 2.7 
3 1.56 0.0030 1.62 10.51 13.15 10.0 11.4 ± 1.8 12.4 ± 1.9 
4 1.40 0.0015 1.43 2.99 3.54 67.0 30.8 ± 2.5 37.2 ± 2.8 
5 1.47 0.0011 1.48 4.24 5.80 44.0 25.9 ± 3.3 30.9 ± 1.6 
6 1.57 0.0010 1.54 4.68 9.99 23.0 22.1 ± 1.7 24.4 ± 1.7 
7 1.48 0.0017 1.51 4.77 5.15 49.0 30.5 ± 3.0 37.8 ± 3.9 
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Table 3.5. Specific Density Measurements and Estimations, Aerodynamic Diameter Calculations, and Deposition Parameters (Mean ± SD, n=3) of 
Formulations Measured by MSLI. 
Formulation 
Density 
(g/cm3) 
Standard 
Dev. 
(g/cm3) 
Estimated 
Proportional 
Density (g/ cm3) 
d50 
(µm) 
dae 
(µm) 
dae < 5 µm  
(%) 
FPF (%) FPF 
(emitted) 
(%) 
8 1.49 0.0013 1.53 5.83 7.11 36.0 19.7 ± 2.1 22.1 ± 2.0 
9 1.64 0.0014 1.56 5.71 10.25 22.0 17.9 ± 1.6 19.7 ± 1.4 
10 1.51 0.0025 1.59 8.13 5.86 43.0 20.5 ± 2.5 23.3 ± 3.1 
11 1.55 0.0018 1.58 8.24 7.31 33.0 13.9 ± 0.8 15.3 ± 1.0 
12 1.72 0.0048 1.58 8.00 10.48 21.0 12.9 ± 1.2 14.1 ± 1.2 
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Figure 3.11. Effect of drug loading on specific density. 
 
Figure 3.12. Effect of protein/polymer ratio on specific density. 
The specific densities of the hybrid formulations were calculated from the proportional 
densities of their individual components and shown in Table 3.5 and Figure 3.13. As can 
be seen, the calculated specific densities were very similar to the measured specific 
densities, indicating that there was no interaction when the components were mixed 
together and spray-dried. As seen earlier in the FIB-milled particles, the addition of PVA 
to the formulations seemed to induce the formation of large, hollow particles. Although 
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hollow particles are generally less dense than solid particles, the inherent specific density 
of PVA was greater than that of BSA, resulting in large, hollow particles with a large 
aerodynamic diameter.  
 
Figure 3.13. Specific density of spray-dried formulations compared with calculated 
density of formulations from the proportional density of individual components. 
The effect of drug loading and protein/polymer ratio on the aerodynamic diameter of the 
particles can be seen in Figure 3.14 and Figure 3.15. Increasing the drug loading resulted 
in a larger aerodynamic diameter although that effect was largely diminished at high 
polymer concentrations at 1:4 protein/polymer ratios. The effect of protein/polymer ratio 
was more amplified by comparison, as was the case for the geometric particle size 
distribution of the particles. The aerodynamic diameter increased greatly when more 
polymer was present due to the higher specific density of PVA-SD compared to CS-SD 
and PVA-SD 
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Figure 3.14. Effect of drug loading on the aerodynamic diameter of the formulations. 
 
Figure 3.15. Effect of protein/polymer ratio on the aerodynamic diameter of the 
formulations. 
In Figure 3.16, we can see the relationship between the FPF and the percentage of 
particles with aerodynamic diameters less than 5 µm. There was a fair fit to the data points 
by least squares linear regression with a coefficient of determination (R2) of 0.76. Of note 
is the high FPF of CS/BSA-50/50-SD. The figure shows that its exceptional FPF was not 
due solely to its low aerodynamic diameter. CS-SD had a similarly low median particle 
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size (2.68 µm) and percentage of particles with aerodynamic diameter under 5 µm, but 
had an FPF of nearly half that of CS/BSA-50/50-SD, confirming the work by (Bosquillon 
et al., (2001); Chew and Chan, (2001)) mentioned earlier that the addition of albumin 
enhances the aerosolisation performance of inhaled powders. Formulation 4, 
CS/BSA/PVA-20/64/16-SD had a low median geometric diameter with a relatively high 
amount of particles with aerodynamic diameter < 5 µm (67%) but had an FPF nearly 20% 
lower than that of CS/BSA-50/50-SD (30.76% vs 50.22%). Clearly, the addition of PVA 
also had dramatic effects on the physicochemical properties of the formulation and will 
have to be studied in greater depth.  
 
Figure 3.16. The relationship between FPF and percentage of particles under 5 µm. 
The in vitro aerosol performance of the formulations was examined using an MSLI. A 
table of the FPF and FPF (emitted) of each formulation as well as the raw drug is shown 
in Table 3.5. Figure 3.17 shows the in vitro deposition of spray-dried powders at different 
protein/polymer ratios while Figure 3.18 shows the effect of drug loading on the FPF. It 
was found that for all protein/polymer ratios, increasing the drug loading resulted in a 
decreased FPF. As discussed in the previous sections, the particle size increased when the 
protein/polymer ratio went from 4:1 to 1:1 to 1:4 (w/w). Although the addition of PVA 
to the formulations tended to form hollow particles, the shells were still rather thick and 
there was no resultant reduction in the density of the particles. It is pertinent to study 
3.3.10 In vitro aerosol performance 
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Figure 3.17 (c) in greater detail as the average particle diameters of the microparticles 
were approximately equal, negating any size related changes to the in vitro aerosolisation 
of the formulations. Here, it is very clear that an increase in drug loading reduces the FPF 
of the formulations. 
 
 
Figure 3.17. In vitro deposition (mean ± standard deviation [n=3]) of spray-dried powders 
at 60 L/min of 20%, 50%, 80% (w/w) CS-loaded microparticles with (a) 4:1, (b) 1:1 and 
(c) 1:4 (w/w) protein/polymer ratios. S1-S4 denote impactor stages, followed by their 
corresponding lower aerodynamic cutoff diameter in parentheses. 
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Figure 3.17. In vitro deposition (mean ± standard deviation [n=3]) of spray-dried powders 
at 60 L/min of 20%, 50%, 80% (w/w) CS-loaded microparticles with (a) 4:1, (b) 1:1 and 
(c) 1:4 (w/w) protein/polymer ratios. S1-S4 denote impactor stages, followed by their 
corresponding lower aerodynamic cutoff diameter in parentheses. 
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Figure 3.18. Effect of drug loading on FPF. 
As previously suggested, the addition of BSA to the formulation did indeed confer it 
increased aerosolisation ability as seen by the two-fold increase in FPF of spray-dried 
CS/BSA-50/50-SD (Formulation 2) to CS-SD (Formulation 1). Interestingly, in Figure 
3.19 (a), the deposition profile of 4:1 and 1:1 protein/polymer ratios for 20% CS drug 
loading were very similar, which may suggest that there may be a limit to the effect of 
BSA on the aerosolisation properties of the formulations at certain drug loadings even 
though the average particle size of the 1:1 formulation (4.77 μm) was larger than that of 
the 4:1 formulation (2.99 μm). In Figure 3.19 (b), we note that even a small addition of 
PVA to the formulation reduced the FPF of the formulation by about half, which was 
almost exactly how much the average particle size diameter increased by (2.67 μm to 5.13 
μm). However, one can safely conclude that the addition of BSA to a hybrid pulmonary 
drug delivery carrier had a positive effect on its aerosol performance while helping to 
reduce the amount of polymer in the delivery system.  
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Figure 3.19. In vitro deposition (mean ± standard deviation [n=3]) of spray-dried powders 
at 60 L/min of (a) 20%, (b) 50%, (c) 80% (w/w) CS-loaded microparticles with 4:1, 1:1 
and 1:4 (w/w) protein/polymer ratios. S1-S4 denote impactor stages, followed by their 
corresponding lower aerodynamic cutoff diameter in parentheses. 
Chapter 3: Hybrid protein-polymer particles for release modulation of inhaled powders 
Leonard Chia - February 2018   69 
 
Figure 3.19. In vitro deposition (mean ± standard deviation [n=3]) of spray-dried powders 
at 60 L/min of (a) 20%, (b) 50%, (c) 80% (w/w) CS-loaded microparticles with 4:1, 1:1 
and 1:4 (w/w) protein/polymer ratios. S1-S4 denote impactor stages, followed by their 
corresponding lower aerodynamic cutoff diameter in parentheses. 
 
Figure 3.20. Effect of protein/polymer ratio on FPF. 
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It is interesting to note the in vitro deposition performance of spray-dried CS/BSA-50/50-
SD. It had, by far, the highest FPF compared to all the other formulations and that the 
addition of just 10% (w/w) of PVA to the formulation decreased the FPF from ~50% to 
30% and even though the amount of BSA in the formulation increased to 64% (w/w) in 
Formulation 4, the FPF was still only about 30%. The increased adhesion that small 
particles have may be the reason why more CS/BSA-50/50-SD was deposited in the 
capsule and device than CS/PVA-50/50-SD. However, upon leaving the device, CS/BSA-
50/50-SD had a low deposition in the throat and stages 1 and 2.  
Dissolution profiles of each formulation are shown for different protein/polymer ratios in 
Figure 3.21 and different drug loadings in Figure 3.22. As there is currently still no 
pharmacopoeia methodology for the evaluation of release rate of pulmonary drug delivery 
systems (Riley et al., (2012)), the dissolution tests were conducted using two commonly 
used types of dissolution apparatus, the USP dissolution apparatus 1 (basket apparatus), 
and the USP dissolution apparatus 4 (flow-through cell) to establish the merits and 
suitability of using each method to analyse the release behaviour of aerosols.  
From both Figure 3.21 and Figure 3.22, it is clear to see that CS was released more quickly 
with the USP dissolution apparatus 1 (basket apparatus) than it was with the USP 
dissolution apparatus 4 (flow-through cell). Given the large volume of dissolution 
medium (900 mL) and a hydrophilic drug, it was unsurprising that this was the case. This 
made distinguishing between the release profiles of different formulations tricky, 
especially when there was a high drug loading [Figure 3.22(c-1)]. Although the USP 
dissolution apparatus 1 (basket apparatus) presented a far more convenient method to 
perform dissolution tests, its large dissolution medium volume and stirring rate did not 
represent physiological conditions in the lung accurately. It could have utility as a quick 
method to determine a formulation’s approximate dissolution profile, but a far more 
nuanced analysis can be had with the USP dissolution apparatus 4 (flow-through cell).  
It is important to note the spread of particle size distributions for the different 
formulations as particle size affects dissolution rate directly. However, one is still able to 
glean certain insights into the characteristics of each excipient in the hybrid formulations. 
It can be seen that for Formulation 2 (CS/BSA-50/50-SD), the addition of BSA did not 
impact the dissolution rate in any way from the spray-dried drug, displaying a similarly 
rapid release within minutes. Paying closer attention to Figure 3.21c, for formulations 
3.3.11 In vitro dissolution studies 
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with 1:4 protein/polymer ratio, we were able to decouple the size effect from the 
dissolution rate and deduce the influence that drug loading has on the dissolution rate as 
all three formulations had a similar particle size distribution. It is clear that the dissolution 
rate increased dramatically when the drug loading was increased to 50% (w/w) and 
beyond as the CS is highly hydrophilic. 
As mentioned earlier, increasing protein/polymer ratio decreased the particle size, which 
also meant we were unable to look at any drug loading amounts where the particle size 
distribution was similar, as was for Figure 3.21c. In general, the dissolution rate increased 
with increasing protein/polymer ratio (although some of that effect has to be attributed to 
the decrease in particle size previously observed). However, it has to be noted that the 
20% drug-loaded formulations were unable to obtain 100% dissolution as the CS may be 
trapped within the PVA matrix with an insufficient pore network for release. A similar 
effect was seen in previous work on antibiotic-loaded bone cement, where a critical 
amount of mesoporous silica was required to form an efficient network for the antibiotic 
to diffuse from the poly(methyl methacrylate)-based bone cement’s polymer matrix (Shen 
et al., (2011)). This effect was less exaggerated for Formulation 4 (●) in Figure 3.22a 
where there was an increased amount of BSA in the carrier, which being highly water-
soluble, may aid in the creation of a network for release. 
For the hybrid protein/polymer carriers we studied, the slowing of the dissolution rate 
was less pronounced at higher drug loadings (Figure 3.21) or greater protein/polymer 
ratios (Figure 3.22), probably because both CS and BSA are highly water-soluble and 
may create pores within the PVA matrix during dissolution. This observation could be 
exploitable, as it would give the formulator the opportunity to regulate the dissolution rate 
of the drug. It must be noted that too much polymer can slow the release to undesirable 
levels and a balance between a slower release rate and efficient release must be reached 
for an optimal release profile. 
As serum albumins are endogenous to the lung, the addition of BSA may also serve to 
reduce the toxicity and increase the biocompatibility of formulations compared to those 
containing a higher proportion of PVA. Although the short-term toxicity of PVA has been 
investigated (R. O. Salama et al., (2009b)), longer-term testing will be needed to support 
chronic use of carrier systems containing it (similar to those described by (Nakamura et 
al., (2001))).  
Investigating Controlled Release Pulmonary Drug Delivery Systems 
72  Leonard Chia - February 2018 
 
Figure 3.21. Effect of drug loading on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution 
apparatus 4 (flow-through cell) (a-2, b-2, and c-2). Dissolution profiles (presented as mean ± standard deviation [n=3]) of 20% (), 50% (), 80% 
() (w/w) CS-loaded microparticles with (a) 4:1, (b) 1:1 and (c) 1:4 (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% 
CS-loaded microparticles with 50% BSA () and 50% PVA () are also shown. 
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Figure 3.21. Effect of drug loading on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution 
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() (w/w) CS-loaded microparticles with (a) 4:1, (b) 1:1 and (c) 1:4 (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% 
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Figure 3.21. Effect of drug loading on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution apparatus 
4 (flow-through cell) (a-2, b-2, and c-2). Dissolution profiles (presented as mean ± standard deviation [n=3]) of 20% (), 50% (), 80% () (w/w) CS-
loaded microparticles with (a) 4:1, (b) 1:1 and (c) 1:4 (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% CS-loaded 
microparticles with 50% BSA () and 50% PVA () are also shown. 
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Figure 3.22. Effect of protein/polymer ratio on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution 
apparatus 4 (flow-through cell) (a-2, b-2, and c-2). Dissolution profiles (presented as mean ± standard deviation [n=3]) of (a) 20%, (b) 50%, (c) 80% 
(w/w) CS-loaded microparticles with 4:1 (), 1:1 () and 1:4 () (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% CS-
loaded microparticles with 50% BSA () and 50% PVA () are also shown. 
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Figure 3.22. Effect of protein/polymer ratio on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution 
apparatus 4 (flow-through cell) (a-2, b-2, and c-2). Dissolution profiles (presented as mean ± standard deviation [n=3]) of (a) 20%, (b) 50%, (c) 80% 
(w/w) CS-loaded microparticles with 4:1 (), 1:1 () and 1:4 () (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% CS-
loaded microparticles with 50% BSA () and 50% PVA () are also shown. 
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Figure 3.22. Effect of protein/polymer ratio on dissolution profiles for USP dissolution apparatus 1 (basket apparatus) (a-1, b-1, c-1) and USP dissolution 
apparatus 4 (flow-through cell) (a-2, b-2, and c-2). Dissolution profiles (presented as mean ± standard deviation [n=3]) of (a) 20%, (b) 50%, (c) 80% 
(w/w) CS-loaded microparticles with 4:1 (), 1:1 () and 1:4 () (w/w) protein/polymer ratios. Dissolution profiles of spray-dried CS (), 50% CS-
loaded microparticles with 50% BSA () and 50% PVA () are also shown. 
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The dissolution profiles of the formulations were fitted to linear plots of widely used 
mathematical models described in Section 2.8 and their coefficients of determination are 
shown in Table 3.6. Raw CS, spray-dried CS and CS/BSA-50/50-SD were highly water-
soluble and had an almost instantaneous release and are difficult to describe accurately 
using the mathematical models. CS/PVA-50/50-SD could be accurately described by a 
few models including first order kinetics and the Baker-Lonsdale model.  
 
Table 3.6. The Coefficients of Determination of Linear Plots of Widely Used Dissolution 
Profile Mathematical Models. 
Formulation 
Zero 
Order 
First 
Order 
Hixson-
Crowell 
Higuchi 
Baker-
Lonsdale 
Korsmeyer-
Peppas 
0 0.293 0.566 0.441 0.536 -0.128 0.968 (3 points) 
1 0.477 0.741 0.670 0.723 0.949 1.000 (2 points) 
2 0.506 0.975 0.879 0.802 0.878 0.915 
3 0.746 0.991 0.952 0.937 0.989 0.987 
4 0.727 0.898 0.847 0.927 0.921 0.982 
5 0.572 0.941 0.794 0.827 0.811 0.984 
6 0.375 0.520 0.466 0.631 0.711 0.993 (3 points) 
7 0.764 0.867 0.836 0.959 0.924 0.976 
8 0.525 0.919 0.801 0.771 0.785 0.998 (3 points) 
9 0.610 0.816 0.743 0.845 0.727 0.944 (3 points) 
10 0.866 0.941 0.919 0.984 0.993 0.973 
11 0.661 0.990 0.964 0.892 0.967 0.963 
12 0.618 0.891 0.808 0.848 0.827 0.972 
 
The spray-dried hybrid formulations were all well described by the Korsmeyer-Peppas 
model. The model is normally used when the release mechanism is not well known and 
when there may be more than one type of release mechanism involved, which perfectly 
fits the nature of the hybrid formulations with a slower dissolving polymer and a highly 
water-soluble protein. However, it has to be noted that due to the quick release nature of 
some of the formulations, only a few measurements were taken before 60% of the drug 
3.3.12 Mathematical models of dissolution profiles 
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was released, which is the degree to which the Korsmeyer-Peppas model is accurate to, 
and so may not fully reflect the closeness of the fit of the formulation to the model.  
As described above, there are many interlinked factors in developing an effective 
controlled release pulmonary drug delivery system for a water-soluble active ingredient. 
It was found that the aerodynamic diameter of the particles provided a fair estimation into 
the FPF of the formulations. The factors that influence the aerodynamic diameter are the 
particles’ specific density, size, and to an extent, microstructure. From the results above, 
it appeared that while the addition of PVA seemed to impart hollowness to the hybrid 
particles, its density was still higher than that of solid BSA particles and hence so was  its 
aerodynamic diameter, resulting in a poorer aerosol performance. 
However, PVA is an effective dissolution modulator so its detrimental effects on the 
aerosol performance have to be balanced with hydrophilic BSA. From our observations, 
we were able to utilise BSA to control the particle size of the formulation and also to 
improve the aerosolisation ability of powders, although one needs to be careful with the 
possibility that it could selectively bind to either the active ingredient or other excipients, 
affecting the release of the AI (Codrons et al., (2003)). Based on the factorial study 
conducted, a formulator should be able to estimate with some certainty, the amount of 
excipients required for a desired dissolution and deposition profile. It is apparent that the 
addition of PVA is detrimental to the aerosol performance of the formulation while being 
able to sustain the release of CS. Formulation 4 perhaps provided the best balance of the 
formulations tested in attaining sustained release of CS and with an acceptable FPF. 
However, the release of CS was limited to about 80% over the time period tested. Taking 
things forward, one could test a formulation with a similar protein/polymer ratio but with 
an increased drug loading between 20% (w/w) and 50% (w/w) as the increased drug 
loading should increase the amount of CS released, albeit while reducing the FPF. It is 
this careful balance that needs to be maintained in considering formulations with 
excipients that appear to be both complementary and contradictory to each other. This 
could be useful in the design of formulations with specific purposes such as paediatric or 
geriatric formulations.  
 
 
3.3.13 Optimised formulation 
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The physicochemical properties of a hybrid protein/polymer drug delivery system were 
studied and shown to be useful for modulating controlled release in vitro. PVA had 
already been shown to be effective in controlling the release of CS in the lung but suffered 
from poor in vitro deposition and a less than ideal particle size distribution. The addition 
of albumin was able to improve the formulation in other areas such as particle size 
distribution and in vitro deposition to create a better-balanced formulation. A formulator 
should be able to utilise BSA as an effective component in the excipient make up for a 
pulmonary drug delivery system as the addition of BSA to the carrier can help to modulate 
the sustained release of active ingredients from the carrier. Furthermore, the addition of 
BSA to the formulations also helped lower the density of the particles and hence their 
aerodynamic diameter for a better aerosol performance. The massive enhancement in the 
aerosol performance when only BSA was added to CS was lost with the addition of a 
small amount of PVA. The effect of PVA on BSA should be studied in further detail to 
understand the mechanism behind this action. These hybrid drug delivery systems show 
that, sometimes, a combination of complementary excipients may be needed to achieve 
the desired effect of certain pulmonary drug delivery systems and that the formulator may 
be able to find the optimal balance between the advantages and limitations of each 
excipient to develop an effective product. 
3.4 Conclusions 
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There is a long history of delivering therapeutics by inhalation (Bryan, (1930)). Since 
then, respiratory ailments such as asthma, chronic obstructive pulmonary disease (COPD) 
4 PHYSICOCHEMICAL EVALUATION 
OF A POORLY WATER-SOLUBLE 
CORTICOSTEROID-AMPHIPHILIC 
POLYMER AMORPHOUS SOLID 
DISPERSION FOR PULMONARY 
DRUG DELIVERY 
4.1 Introduction 
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and infections can all be treated locally. This entails a reduction in the side effects of 
systemic delivery of active pharmaceutical ingredients (APIs) and the required dose may 
be reduced as hepatic first pass metabolism is avoided (Olsson et al., (2011)). Systemic 
delivery of drugs to the lung is also an attractive prospect for pulmonary delivery due to 
the large surface area for absorption in the alveolar epithelium (Patton and Byron, (2007)). 
However, the poor solubility of APIs is one of the most challenging issues in the 
development of many pharmaceutical products and orally inhaled products are no 
exception. An estimated 40% of drugs listed in the US Pharmacopoeia is listed as poorly 
water-soluble, or insoluble (Williams et al., (2013)). These drugs have poor 
bioavailability when administered because of poor solubility in biological fluids, and 
often fail to be commercialised. The dissolution rate is often the rate limiting step for 
Biopharmaceutical Classification System (BCS) Class II drugs, which have low solubility 
and high permeability, and there are several strategies which can be employed to mitigate 
this. These include particle size reduction (Jinno et al., (2006)), co-crystallisation, the use 
of polymeric micelles (Liu et al., (2008); Wais et al., (2016)), inclusion in cyclodextrins 
(Uekama et al., (1983); Vartiainen et al., (2017)), nanocrystalline (De Smet et al., (2014)) 
or amorphous forms (Chen et al., (2016); Prasad et al., (2014)) of the API. 
An increased bioavailability will be beneficial for poorly water-soluble drugs adminstered 
by pulmonary delivery. While slowing the rate of release can be a strategy to prolong the 
retention of drugs in the lung and hence its effect, a release rate that is too slow will cause 
the drug to be more susceptible to clearance mechanisms (Mobley and Hochhaus, (2001)) 
and cause the drug concentration to dip below therapeutic levels. Insoluble particles will 
likely be engulfed by alveolar macrophages while a soluble particle will dissolve in lung 
fluid and exert its therapeutic action (Davies and Feddah, (2003)). Yet, not all the 
formulation strategies highlighted above can be applied to such systems. A combination 
of efficient lung clearance mechanisms and a limited pool of regulatory approved 
excipients for inhalation has been a major hurdle in developing viable pulmonary drug 
delivery systems (Smyth and Hickey, (2011)).  
Amorphous solid dispersions have been a popular strategy in improving the dissolution 
behaviour of orally ingested drugs and it has also seen uptake for pulmonary delivery 
systems (Chen et al., (2016); Giunchedi et al., (2001); Wauthoz and Amighi, (2015)). 
Spray drying is one of the more common approaches to obtain amorphous solid 
dispersions (Seville et al., (2007); Vehring, (2008)). The amorphous state is 
thermodynamically less stable than the crystalline state and that leads to an improvement 
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in the dissolution rate (Hancock et al., (2002)). However, one of the foremost concerns 
regarding the amorphous state is its tendency to re-crystallise, which decreases the 
dissolution rate of the drug (Hancock et al., (1995); Yoshioka et al., (1994)). This is 
undesirable in the pharmaceutical field where active ingredients in their amorphous and 
crystalline form often have very different pharmacokinetic and pharmacodynamic 
profiles. This is especially pertinent for pulmonary delivery, where the surface 
characteristics of spray-dried powders have a sizeable influence on the FPF, which is an 
in vitro measurement of the amount of particles that will reach the lungs. Re-
crystallisation of spray-dried particles during processing or storage could affect the 
particle surface and hence its FPF (Maa et al., (1998)). 
Soluplus® is a graft co-polymer (polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol) introduced by BASF as a solubiliser. It has the ability to form solid solutions and 
its amphiphilic structure helps to solubilise poorly water-soluble drugs in aqueous media 
with the formation of micelles. Soluplus® has been used to formulate amorphous solid 
dispersions, especially with hot melt extrusion (Djuris et al., (2013); Jing et al., (2015); 
Lu et al., (2015)), but also with spray-drying (Davis, Mark T., Potter, Catherine B., 
Mohammadpour and Maryam, Albadarin, Ahmad B., Walker, (2017); Lavra et al., 
(2016)). Recently, Soluplus® was also investigated for the delivery of insulin via 
inhalation (Andrade et al., (2015)) as well as a dry powder for nasal drug delivery (Pozzoli 
et al., (2017)). It was found that lyophilised insulin-Soluplus® formulations did not have 
significant in vitro toxicity to respiratory cell lines, suggesting that it could be a viable 
candidate as an excipient in pulmonary drug delivery, especially given its unique 
bifunctional character in forming solid solutions, and micelles with a low critical micelle 
concentration (CMC). 
Beclomethasone dipropionate (BDP) is a corticosteroid that is often prescribed for the 
treatment of asthma and chronic obstructive pulmonary disease to fight inflammation 
(Daley-Yates et al., (2001); Sakagami et al., (2002)). It is used as a form of prophylaxis 
treatment with long-acting bronchodilators to control asthma symptoms. However, its 
poor water solubility (0.16 μg/mL) may impact the bioavailability of drugs in the 
pulmonary tract. 
Here, the spray-dried formulation of BDP and Soluplus® was investigated for its 
physicochemical properties such as dissolution and aerosolisation performance as well as 
physical stability. The purpose of the study was to determine if Soluplus® is a suitable 
excipient for the formulation of an amorphous solid dispersion of poorly water-soluble 
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drugs for pulmonary drug delivery.  
BDP was supplied from Junda Pharmaceutical Company Ltd. (Changzhou, China) and 
Soluplus® (Mr 90,000–140,000 g/mol) was kindly provided by BASF (Ludwigshafen, 
Germany). Polyvinylpyrrolidone (Mr 130,000 g/mol) (PVP K130) and sodium dodecyl 
sulphate (SDS) were procured from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade 
methanol and acetonitrile were obtained from Duksan Pure Chemicals Co., Ltd 
(Gyeonggi-do, Republic of Korea). Ultrapure water was used in all the experiments. 
A set of formulations with a range of drug loadings (10, 15, 20, 30 and 40% w/w) were 
prepared. Pure BDP and 20% (w/w) drug loaded BDP-PVP K130 were also spray-dried 
for comparison. Typically, varying amounts of active ingredient were measured out and 
dissolved in methanol before the addition of polymer. The drug and polymer were 
allowed to dissolve fully overnight. Spray drying was performed on a laboratory scale 
spray dryer equipped with a high performance separating cyclone and 0.7 mm nozzle (B-
290 Mini Spray Dryer, BÜCHI Labortechnik AG, Flawil, Switzerland). The mini 
spray dryer was operated in a ‘closed loop’ configuration with the Inert Loop B -
295 accessory at the following conditions: inlet temperature 80 °C, outlet 
temperature ~50 °C, aspirator gas flow rate 35 m3/h, atomising spray air flow rate 
473 L/h and solution feed rate at 4 mL/min. All spray-dried powders were dried 
overnight in a vacuum desiccator filled with silica beads after collection.  
BDP was cryogenically-milled as well, using a mixer mill (Mixer Mill MM 301, 
Retsch GmbH, Haan, Germany) equipped with a 50 mL stainless steel jar and a 
Ø50 mm grinding ball. Approximately 3 g of crystal line drug and the grinding 
ball were placed into the jar and pre-cooled in liquid nitrogen for ten minutes 
before being milled for 300 min at 20 Hz. Pre-cooling of the chamber was 
performed at two-minute intervals. 
A physical mixture of cryo-milled (CM) BDP and Soluplus® was produced by 
4.2 Materials and methods 
4.2.1 Materials 
4.2.2 Methods 
4.2.2.1 Particle preparation 
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mixing 10% (w/w) cryo-milled BDP and 90% (w/w) raw Soluplus® in a bottle 
which was then capped and sealed tightly. The bottle was then placed into a multi-
axis shaker-mixer (Alphie 3, Hexagon Product Development Pvt. Ltd, Gujarat, India) for 
three hours at 75 RPM to ensure complete mixing. 
The thermal profiles of the powders were determined by differential scanning calorimetry 
(DSC). Experiments were conducted on a Mettler Toledo DSC 3 (Greifensee, 
Switzerland). Approximately 5 mg of powder was placed into an aluminium crucible. 
Measurements were taken at a heating rate of 10 °C/min. 
A United State Pharmacopoeia (USP) dissolution apparatus 4 (flow-through cell) (DFZ 
720 flow-through-cell dissolution tester, Erweka GmbH, Heusenstamm, Germany) was 
used in the ‘open-loop’ configuration to conduct release studies of BDP. The temperature 
of the water baths surrounding the cells was maintained at 37 °C. 0.2% (w/v) sodium 
dodecyl sulphate solution was maintained at 37 °C before being pumped through the 
system using a peristaltic pump (IPC 8 microprocessor-controlled dispensing pump, 
Ismatec SA, IDEX Health & Science GmbH, Wertheim, Germany) at a constant flow rate 
of approximately 1.6 mL/min. A schematic of the dissolution apparatus setup is shown in 
Figure 4.1. Powders containing 20 mg of active ingredient, BDP, were weighed out and 
sandwiched between 1 mm glass beads (to promote laminar flow), which was bounded 
by 0.45 µm hydrophilic PTFE filters. The area exposed to vertical flow was 1.25 cm in 
diameter and dissolution medium exiting the flow-through cell was collected in beakers. 
At pre-determined time intervals, new collection beakers were put in place. The 
dissolution media collected in separate beakers were passed through 0.22 µm syringe 
filters and diluted with methanol (1:1 v/v) before being analysed for their concentrations 
using HPLC. Each formulation was tested in triplicate.  
4.2.2.2 Thermal analysis 
4.2.2.3 In vitro dissolution studies 
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Figure 4.1. Schematic of Erweka DFZ 720 USP dissolution apparatus 4 (flow-through 
cell) in the ‘open loop’ configuration. 
BDP content in the spray-dried powders was analysed via HPLC (1100 series; Agilent 
Technologies, Santa Clara, CA, USA) using a Zorbax Eclipse Plus C-18 column (4.6 mm 
x 250 mm, 5 µm) (Agilent, Technologies, Santa Clara, CA, USA) at a flow rate of 1 
mL/min and an injection volume of 50 µL. Acetonitrile-water (65:35 v/v) was used as the 
mobile phase and the UV detection wavelength utilised was 254 nm. The retention time 
of BDP was approximately 11.8 min. 
The co-spray dried powders were stored under accelerated stress test conditions 
recommended by the International Conference on Harmonisation (ICH) – ICH Q1A (R2) 
4.2.2.4 Drug assay 
4.2.2.5 Stability testing 
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of 40 °C/75% RH in open pans and were tested for their crystallinity with XRD at frequent 
time intervals. 
The spray-drying yields, experimental drug loadings and entrapment efficiencies of the 
spray-dried formulations are shown in Table 4.1. The spray-drying yields were mostly 
high for BDP-Soluplus® formulations (> 70%) compared to the typical spray-drying yield 
of 50-70% achieved with the same spray-dryer for inhalable particles (“Laboratory scale 
spray drying Of inhalable drugs: A review,” (2010)), with the exception of BDP-
Soluplus®-30, due in part to the difficulty for even the high performance cyclone to 
separate small particles from the gas stream. Poor yields were also obtained for pure BDP 
and BDP-PVP K130. As will be seen in the moisture sorption data, BDP-PVP K130-20 
was the most hygroscopic formulation and that may have been reflected in the increased 
difficulty to collect the particles in the spray-dryer. The experimental drug loadings were 
close to their theoretical ratios and the entrapment efficiency was close to 100% for all 
formulations, confirming spray-drying as a suitably efficacious method for preparing 
drug-loaded particles. 
 
Table 4.1. Spray-drying Yield, Drug loading and Entrapment Efficiency of Spray-dried 
Formulations. 
Sample 
Spray-drying 
Yield (%) 
Theoretical 
Drug 
Loading (%) 
Experimental 
Drug Loading 
(%) 
Entrapment 
Efficiency (%) 
BDP-SD 48.5 - - - 
BDP-Soluplus®-10 76.0 10 10.2 102.2 
BDP-Soluplus®-15 81.3 15 14.4 95.7 
BDP-Soluplus®-20 84.2 20 19.5 97.6 
BDP-Soluplus®-30 40.4 30 28.5 95.1 
BDP-Soluplus®-40 81.8 40 38.3 95.8 
BDP-PVP K130-20 56.2 20 18.2 91.1 
4.3 Results and discussion 
4.3.1 Yield, drug loading, and entrapment efficiency 
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As seen in Figure 4.2, all freshly prepared formulations displayed a broad diffuse peak, 
indicating X-ray amorphicity, except for BDP-SD which showed small crystalline peaks. 
It is, however, important to note that 30 cryo-milling cycles were required before an X-
ray amorphous sample was obtained for cryo-milled BDP (BDP-CM), highlighting the 
difficulty in obtaining an amorphous form of BDP using either spray drying or cryo-
milling. A physically mixed sample of cryo-milled BDP and raw Soluplus® (BDP-
Soluplus®-PM) was X-ray amorphous after preparation. 
 
Figure 4.2. X-ray diffractograms of freshly prepared BDP samples. 
The thermal profiles of the spray-dried powders are shown in Figure 4.3. BDP-SD showed 
a melting endotherm at 212 °C which agrees well with the melting point of the crystalline 
drug (Buttini et al., (2014)). This endotherm was distinctly absent in all the other spray-
dried formulations, which confirmed the amorphous form shown in the XRD 
measurements.  
4.3.2 Powder crystallinity 
4.3.3 Thermal analysis 
Chapter 4: Physicochemical evaluation of a poorly water-soluble corticosteroid-amphiphilic polymer 
amorphous solid dispersion for pulmonary drug delivery 
Leonard Chia - February 2018   89 
 
Figure 4.3. DSC thermogram of spray-dried formulations. a) BDP-SD, (b) BDP-
Soluplus®-10, (c) BDP-Soluplus®-15, (d) BDP-Soluplus®-20, (e) BDP-Soluplus®-30, (f) 
BDP-Soluplus®-40, (g) BDP-PVP K130-20. 
Moisture sorption isotherms of the spray-dried formulations are shown in Figure 4.4. As 
expected, the lipophilic BDP had a very low maximum mass change of only 2% (w/w) at 
90% RH. There was no evidence of moisture-induced re-crystallisation and it was noted 
that BDP-PVP K130-20, which does not possess a hydrophobic group like amphiphilic 
Soluplus®, had a change in mass (33.17%) which was twice as much as BDP-Soluplus®-
20 (16.32%) which also possessed 20% (w/w) of BDP as BDP-PVP K130-20. Due to the 
addition of amphiphilic Soluplus®, which has a hydrophilic group, the relative moisture 
sorption of the spray-dried formulation increased with increasing amount of Soluplus® 
added. Upon closer examination, this relationship was found to be a linear one from 10-
40% (w/w) of Soluplus® (Figure 4.5), although not from 0-10% (w/w) Soluplus®.  
4.3.4 Moisture sorption 
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Figure 4.4. DVS sorption isotherms of spray-dried formulations. 
 
Figure 4.5. Moisture sorption at 50% RH plotted as a function of Soluplus® percentage in 
formulation. Spray-dried BDP is shown as (). 
The surface composition of the raw, as well as spray-dried drug and polymers, were 
estimated from XPS peaks and shown in Table 4.2. The surface composition of BDP 
compared well with both the calculated theoretical atomic percentage as well as other 
4.3.5 Surface composition estimation 
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experimentally-derived measurements (Bouhroum et al., (2010)) reported in literature. 
While the experimentally-derived surface compositions were similar for that of the raw 
and spray-dried forms of BDP and PVP K130, there was a noticeable difference between 
that of raw Soluplus® and spray-dried Soluplus®. A greater percentage of carbon and 
nitrogen was found on the surface for spray-dried Soluplus® which suggests that a certain 
degree of surface alteration by the spray-drying process was present. 
 
Table 4.2. Surface Composition (Atomic %) of Raw and Spray-dried Drug and Polymer 
Components. 
Sample Carbon (%) Oxygen (%) Chlorine (%) Nitrogen (%) 
BDP-raw 81.7 15.6 2.7 - 
BDP-SD 81.5 16.3 2.2 - 
Soluplus®-raw 72.7 27.1 - 0.3 
Soluplus®-SD 79.1 15.6 - 5.2 
PVP K130-raw 79.5 10.8 - 9.6 
PVP K130-SD 79.2 11.7 - 9.2 
 
In Table 4.3, the estimated surface coverage of the spray-dried formulations of drug and 
polymer can be seen. As can immediately be noted, both polymers dominated the surface 
coverage, with only minuscule amounts of BDP found on the surface of the particles. 
Increasing the drug loading only made a small difference in the amount of BDP on the 
surface of the particles. This surface coverage may explain the increased physical stability 
of the spray-dried formulations with lower drug loadings, by inhibiting nucleation and re-
crystallisation through mechanical obstruction (Priemel et al., (2013)).  
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Table 4.3. Estimated Surface Coverage (Wt %) of Spray-dried Formulations. 
Sample BDP-SD (%) Soluplus®-SD (%) PVP K130-SD (%) 
BDP-Soluplus®-10 0.03 99.97 - 
BDP-Soluplus®-15 0.14 99.86 - 
BDP-Soluplus®-20 0.17 99.83 - 
BDP-Soluplus®-30 0.16 99.84 - 
BDP-Soluplus®-40 0.41 99.59 - 
BDP-PVP K130-20 0.24 - 99.76 
 
The particle size distribution of the spray-dried formulations can be found in Table 4.4. 
The particle size and span of the spray-dried BDP-Soluplus® formulations were found to 
be largely similar, due in part that they were all spray-dried with the same conditions. The 
spray-dried particles were in the respirable range, with the exception of BDP-PVP K130-
20, which was found to have a much larger span, with d90 of 64.74 µm.  
 
Table 4.4. Volume Particle Size Distribution of Spray-dried Formulations. 
Sample d10 (µm) d50 (µm) d90 (µm) Span (µm) 
BDP-SD 1.20 ± 0.07 2.35 ± 0.05 4.62 ± 0.34 1.45 
BDP-Soluplus®-10 1.52 ± 0.01 3.00 ± 0.02 5.73 ± 0.05 1.40 
BDP-Soluplus®-15 1.38 ± 0.07 2.76 ± 0.06 5.47 ± 0.30 1.48 
BDP-Soluplus®-20 1.26 ± 0.11 2.84 ± 0.08 6.11 ± 0.19 1.71 
BDP-Soluplus®-30 0.76 ± 0.02 1.47 ± 0.05 2.79 ± 0.19 1.38 
BDP-Soluplus®-40 1.09 ± 0.05 2.27 ± 0.04 4.69 ± 0.29 1.59 
BDP-PVP K130-20 1.40 ± 0.01 5.80 ± 0.11 64.74 ± 4.39 10.92 
 
The particle morphologies of spray-dried Soluplus®, spray-dried BDP, spray-dried BDP-
Soluplus®, spray-dried PVP K130, and spray-dried BDP-PVP K130 formulations can be 
seen in Figure 4.6. All the spray-dried particles were generally spherical in shape. Spray-
dried Soluplus® (Figure 4.6a) had a dimpled and corrugated surface while spray-dried 
BDP was more spherical, although plate-shaped crystals could be made out on some 
particles. This is in good agreement with the XRD results where it was observed that 
4.3.6 Particle morphology and size distribution  
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spray-dried BDP was unable to form fully amorphous BDP. The spray-dried BDP-
Soluplus® formulations had a similar surface morphology to that of Soluplus®-SD. Some 
fibres were seen for BDP-PVP K130-20 (Figure 4.6i). These fibres do not appear in all 
the other formulations and hence can be assumed to be ascribed to PVP K130. Traces of 
these fibres can also be seen near the top of the left column image for spray-dried PVP 
K130 (Figure 4.6g). The particles seen in Figure 4.6h were also smaller than the rest with 
concave saucer-like surfaces. These small particles (< 1 µm) would probably be very 
cohesive and may aggregate together to account for the large d90 values seen for BDP-
PVP K130-20.  
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Figure 4.6. Field emission scanning electron micrographs of spray-dried (a) Soluplus®, 
(b) BDP, (c) BDP-Soluplus®-10, (d) BDP-Soluplus®-15, (e) BDP-Soluplus®-20, (f) BDP-
Soluplus®-30, (g) BDP-Soluplus®-40, (h) PVP K130-SD, and (i) BDP-PVP K130-20. 
Images in the right column are magnifications of those in the corresponding left column. 
Scale bars of the images in the left column indicate 10 µm and the scale bars of the images 
in the right column indicate 1 µm. 
 
 
(a) (a) 
(b) (b) 
(c) (c) 
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Figure 4.6. Field emission scanning electron micrographs of spray-dried (a) Soluplus®, 
(b) BDP, (c) BDP-Soluplus®-10, (d) BDP-Soluplus®-15, (e) BDP-Soluplus®-20, (f) BDP-
Soluplus®-30, (g) BDP-Soluplus®-40, (h) PVP K130-SD, and (i) BDP-PVP K130-20. 
Images in the right column are magnifications of those in the corresponding left column. 
Scale bars of the images in the left column indicate 10 µm and the scale bars of the images 
in the right column indicate 1 µm. 
(e) (e) 
(f) (f) 
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Figure 4.6. Field emission scanning electron micrographs of spray-dried (a) Soluplus®, 
(b) BDP, (c) BDP-Soluplus®-10, (d) BDP-Soluplus®-15, (e) BDP-Soluplus®-20, (f) BDP-
Soluplus®-30, (g) BDP-Soluplus®-40, (h) PVP K130-SD, and (i) BDP-PVP K130-20. 
Images in the right column are magnifications of those in the corresponding left column. 
Scale bars of the images in the left column indicate 10 µm and the scale bars of the images 
in the right column indicate 1 µm. 
The aerosol performance of the spray-dried formulations is shown in Figure 4.7, and 
4.3.7 In vitro aerosol performance 
(i) (i) 
(h) (h) 
(g) (g) 
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Table 4.5. Spray-dried BDP and spray-dried BDP-Soluplus® formulations all had an FPF 
of approximately 40%, with a large percentage of particles found in stages 3 and 4, 
indicating greater deposition in the lower airways. The amount of particles trapped in the 
device increased for BDP-Soluplus®-30 and BDP-Soluplus®-40, due to the increased 
cohesive nature of the particles resulting from their smaller particle size, heightening the 
gap between the FPF and FPF (emitted) for those formulations. It is also worth noting 
that the FPFs of BDP-Soluplus®-15 and BDP-Soluplus®-20 were higher than that of BDP-
SD despite having larger mean particle sizes, suggesting that the collapsed, dimpled 
surface morphology of the particles seen in Figure 4.6d and Figure 4.6e, may have 
contributed to an increased aerosolisation ability of the particles, in the same way 
wrinkled surfaces do (Healy et al., (2014)). 
 
Figure 4.7. In vitro deposition of (a) BDP-SD, (b) BDP-Soluplus®-10, (c) BDP-
Soluplus®-15, (d) BDP-Soluplus®-20, (e) BDP-Soluplus®-30, (f) BDP-Soluplus®-40, (g) 
BDP-PVP K130-20. Data presented as mean ± SD (n=3). S1-S4 denote impactor stages, 
followed by their corresponding lower aerodynamic cutoff diameter in parentheses. 
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Table 4.5. Deposition Parameters (Mean ± SD, n=3) of Different Formulations Measured 
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by MSLI. 
Sample FPF (%) FPF (emitted) (%) 
BDP-SD 38.8 ± 3.0 50.2 ± 3.6 
BDP-Soluplus®-10 33.8 ± 3.6 41.1 ± 3.6 
BDP-Soluplus®-15 46.9 ± 1.2 56.2 ± 0.9 
BDP-Soluplus®-20 44.1 ± 1.1 52.2 ± 1.3 
BDP-Soluplus®-30 48.0 ± 1.3 70.4 ± 2.8 
BDP-Soluplus®-40 44.4 ± 6.2 59.5 ± 5.8 
BDP-PVP K130-20 30.8 ± 2.5 39.1 ± 3.6 
 
In Figure 4.8, the relationship between the mean particle size of the spray-dried 
formulations and their FPF and FPF (emitted) can be studied. There was a very clear 
relationship between the particle size and the FPF. This suggests that the particles were 
not likely to be porous or hollow. Porous or hollow particles may have a large geometric 
diameter measured by laser scattering, but due to their low density, a low MMAD and 
hence a higher than expected FPF (Edwards et al., (1997)). BDP-PVP K130-20 had poor 
aerosolisation ability which will doubtless be due, in part, to its large d90 values, possibly 
from agglomerated particles. 
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Figure 4.8. FPF and FPF (emitted) of spray-dried formulations overlaid with the mean 
particle size (secondary axis) of each formulation. 
BDP is a Biopharmaceutical Classification System (BCS) Class II drug with low 
solubility and high permeability. It is limited by dissolution rate kinetics (Daley-Yates et 
al., (2001)) and would hence benefit from an increase in solubility for absorption in the 
lungs.  
The dissolution rate profiles of spray-dried BDP-Soluplus® formulations alongside raw 
BDP, spray-dried BDP and spray-dried BDP-PVP K130 are shown in Figure 4.9. 
According to the Noyes-Whitney equation (Chapter 1.4, Equation 3 and 4), the rate of 
dissolution is proportional to the surface area of the solid (Noyes and Whitney, (1897)). 
As spray-dried BDP had a far lower mean particle size than raw BDP, it should be 
expected to have a faster dissolution rate than the crystalline drug. However, this cannot 
be seen in Figure 4.9, with both raw and spray-dried drug having a similarly limited and 
slow release. With greater Soluplus® content, the dissolution rate and amount dissolved 
4.3.8 In vitro dissolution studies 
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both increased. This effect is especially marked for BDP-Soluplus®-10 and BDP-
Soluplus®-15, while BDP-Soluplus®-20, BDP-Soluplus®-30 and BDP-Soluplus®-40 all 
had very similar dissolution profiles. BDP-PVP K130-20 had an initial burst release of 
drug which plateaued after  an hour, finally releasing a similarly low amount of BDP as 
spray-dried and raw BDP. Soluplus® has a low critical micelle concentration (CMC) of 
7.6 mg/mL. However, the spray-dried formuliatons were likely unable to form micelles 
in the USP dissolution apparatus 4 (flow-through cell) cell due to the slow flow rate. 
Visually, the distinct hue of turbidity apparent after micelle formation was absent. Further 
tests could be conducted on the aliquots to determine the formation of micelles (using 
dynamic light scattering) and further, the ability of the micelles to solubilise the drug by 
testing its crystallinity with small angle x-ray spectroscopy (SAXS).  
 
Figure 4.9. In vitro dissolution profiles of raw-BDP (), BDP-SD (), spray-dried BDP-
Soluplus®-10 (), BDP-Soluplus®-15 (), BDP-Soluplus®-20 (), BDP-Soluplus®-30 
(), BDP-Soluplus®-40 (), BDP-PVP K130-20 (). 
Although there is still no regulatory approved dissolution test for orally inhaled products, 
the bioavailability and therapeutic action of inhaled particles are based on the amount of 
particles that dissolve in the fluid in the respiratory tract (Riley et al., (2012)). Yet, due 
to the complexity of the human respiratory system, there still does not exist a suitable 
dissolution testing apparatus to satisfactorily measure the dissolution profile of inhaled 
products. The USP dissolution apparatus 4 (flow-through cell) is one such apparatus that 
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has been mooted as a possible candidate for measuring dissolution in the lung. First 
introduced in 1957 by the FDA (Langenbucher et al., (1989)), the flow-through cell is the 
preferred dissolution apparatus for measuring the dissolution profile of  poorly water-
soluble drugs due to its ability to maintain sink conditions in the ‘open-loop’ 
configuration, where fresh medium flows over the sample continuously (Fotaki, (2011)). 
When used in this study, the samples were placed in the middle of the USP dissolution 
apparatus 4 (flow-through cell) cell, surrounded by 1 mm diamater glass beads. The tight 
packing of the powder in the cell may have contributed to the formation of an observed 
viscous gel layer, in which sink conditions may not be present locally. One can conclude 
that the USP dissolution apparatus 4 (flow-through cell) in this setup is not a good 
analogue for the lung, nor does it claim or attempt to be. The in vitro drug release profiles 
obtained from the USP dissolution apparatus 4 (flow-through cell) dissolution test give 
an indication of what the release could be like in the lung, but should not be used to 
correlate what happens in vivo. The lung has a far larger surface area than the USP 
dissolution apparatus 4 (flow-through cell) cell so the inhaled dose is expected to be much 
more dispersed and the formation of a gel cake far less likely. 
The presence of the viscous gel layer is probably a key reason why so little of the sample 
is released even after seven hours. This was referred to for a Soluplus®-Budesonide 
physical mixture in work conducted by Pozzoli et al., (2017). Analysis of the inherent 
properties of Soluplus® (Shi et al., (2016)) showed that its viscosity increased with 
temperature in media such as water and PBS, with dramatic increases from 37 °C to 42 
°C. The possibility of the formation of strong gel networks at the dissolution test 
conditions could explain the slow and incomplete release of the loaded drugs, especially 
at a low flow rate like the one used in this test. Further analysis of the formation of the 
gel will give a better idea of its effect on drug release. The formation of such a gel network 
could also give rise to possibilities in forming sustained release formulations (Miyazaki 
et al., (2009)), once its formation is better understood. 
The dissolution profiles of the formulations described in Section 4.3.8 were fitted to 
commonly used mathematical models and their coefficients of determination are shown 
in Table 4.6. The spray-dried BDP-Soluplus® formulations were found to fit the Higuchi, 
Korsmeyer-Peppas and Baker-Lonsdale models well. This suggests that the dissolution 
process was largely diffusion based from microspheres and with possibly more than one 
4.3.9 Mathematical models for dissolution profiles 
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mode of release mechanism, which describes the system well. BDP-PVP K130-20 did 
not fit any model particularly well and was best described by the Korsmeyer-Peppas 
model. It has to be taken in mind that, as mentioned above, the dissolution profiles were 
not fully resolved by the USP dissolution apparatus 4 (flow-though cell) and while it 
provided a basis for comparison between formulations, it would not be at all indicative of 
the actual dissolution process of the powders.  
 
Table 4.6. The Coefficient of Determination of Linear Plots of Most Widely Used 
Dissolution Profile Mathematical Models. 
Sample 
Zero 
Order 
First 
Order 
Hixson-
Crowell 
Higuchi 
Baker-
Lonsdale 
Korsmeyer-
Peppas 
BDP-raw 0.999 0.999 0.999 0.954 0.911 0.999 
BDP-SD 0.968 0.968 0.968 0.970 0.957 0.758 
BDP-Soluplus®-10 0.726 0.729 0.728 0.911 0.743 0.961 
BDP-Soluplus®-15 0.836 0.838 0.837 0.968 0.919 0.988 
BDP-Soluplus®-20 0.907 0.908 0.908 0.993 0.988 0.975 
BDP-Soluplus®-30 0.851 0.853 0.852 0.979 0.951 0.983 
BDP-Soluplus®-40 0.794 0.795 0.795 0.952 0.905 0.900 
BDP-PVP K130-20 0.511 0.512 0.512 0.743 0.240 0.866 
 
One of the foremost concerns regarding spray-dried formulations is that the product is 
usually amorphous. This constitutes a challenge to the physical stability of the 
formulations as the amorphous state will tend to the more thermodynamically stable 
crystalline state with time. This is undesirable in the pharmaceutical field where active 
ingredients in the amorphous and crystalline form often have very different 
pharmacokinetic and pharmacodynamic profiles. Especially pertinent for pulmonary 
delivery, the surface characteristics of spray-dried powders have a sizeable influence on 
the FPF. Re-crystallisation of spray-dried particles could affect the particle surface and 
hence its FPF (Maa et al., (1998)).  
The stability tests for the spray-dried formulations as well as cryo-milled BDP and 
physically mixed BDP-Soluplus® at accelerated storage conditions of 40 °C and 75% RH 
4.3.10 Stability studies 
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are shown in Figure 4.10. As noted earlier, most formulations were amorphous 
immediately after formulation with the exception of BDP-SD (Figure 4.10a). The micro-
peaks present in the fresh BDP-SD sample developed into peaks with greater intensity 
and definition within a day of storage at the accelerated stress test conditions. Similarly, 
for BDP-CM (Figure 4.10h), well-defined crystalline peaks developed within just two 
days of storage at accelerated stress test conditions. 
 
Figure 4.10. X-ray diffractograms of spray-dried BDP formulations after storage at 
accelerated stress test conditions of 40 °C/75% RH for up to nine months. (a) BDP-SD, 
(b) BDP-Soluplus®-10, (c) BDP-Soluplus®-15, (d) BDP-Soluplus®-20, (e) BDP-
Soluplus®-30, (f) BDP-Soluplus®-40, (g) BDP-PVP K130-20, (h) Cryo-milled BDP, (i) 
Physically mixed 20% (w/w) BDP-CM and 80% (w/w) Soluplus®. 
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For the co-spray dried BDP-Soluplus® samples, physical stability decreased with 
increasing drug loading. At 40% (w/w) drug loading (BDP-Soluplus®-40, Figure 4.10f), 
small peaks started appearing in the X-ray diffractogram after one day, which developed 
into well-defined crystalline peaks by one week. Peaks appeared for BDP-Soluplus®-30 
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(Figure 4.10e) after a week and a single peak at ~ 8° started manifesting for BDP-
Soluplus®-20 after a month. BDP-Soluplus®-10 and BDP-Soluplus®-15 remained X-ray 
amorphous for the entire six-month duration of the accelerated stability study. By 
contrast, the physically mixed sample of amorphous cryo-milled BDP and raw Soluplus® 
started re-crystallising after just one day at accelerated storage conditions.  
BDP-PVP K130-20 started re-crystallising after just one day, compared to a month for 
BDP-Soluplus®-20. Small peaks appeared after a day at accelerated stress test conditions 
and developed over a month into a series of peaks compared to the single peak at ~8° for 
BDP-Soluplus®-20, suggesting that PVP K130 is unable to stabilise amorphous BDP to 
the degree that Soluplus® can. 
As mentioned earlier, re-crystallisation brings about changes in the morphology and 
particle surface which could be detrimental to its aerosolisation ability, as well as 
removing the dissolution rate enhancement that the amorphous form brings. The results 
show that high temperature and humidity affect the physical stability of the formulations. 
However, this could be mitigated using moisture-protective blister packaging.  
The viability of Soluplus® as an excipient for formulating poorly water-soluble BDP for 
pulmonary delivery was investigated. While amorphous BDP was difficult to obtain 
through spray-drying or cryo-milling, co-spray dried BDP-Soluplus® were able to form 
amorphous powders easily. These co-spray dried formulations were able to achieve high 
entrapment efficiencies and yields and were also X-ray amorphous at accelerated stress 
test conditions up to a drug loading of 15% (w/w). The co-spray dried formulations were 
of a respirable size (d50 ~ 2.5 µm) and achieved FPFs of up to 48%. The amorphous, co-
spray dried BDP-Soluplus® powders were able to achieve up to 2X faster dissolution rate 
with 7X more BDP released although the USP dissolution apparatus 4 (flow-through cell) 
was not able to fully investigate the dissolution behaviour of the powders. It was 
hypothesised that a gel was formed due the high hydrophilicity of Soluplus, and diffusion 
through the gel layer competed with the dissolution rate enhancement that the amorphous 
form of BDP embodies. The co-spray dried BDP-Soluplus® powders were compared with 
another commonly used hydrophilic excipient for stabilising amorphous substances, PVP. 
The co-spray dried BDP-PVP powder was unable to display the same narrow particle size 
distribution, FPF, dissolution rate enhancement and physical stability as the similarly 
4.4 Conclusions 
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loaded co-spray dried BDP-Soluplus®. Co-spray dried BDP-Soluplus® has shown 
potential to be a possible viable formulation for poorly water-soluble drugs for pulmonary 
delivery, however, further studies should be conducted about the gel-forming behaviour 
of Soluplus® and its suitability for use as a sustained release excipient instead.  
Small angle X-ray scattering (SAXS) could be used to study the formation of this gel and 
help in the identification of steps to minimise its formation and also to confirm that the 
gel is indeed responsible for the limited release of active ingredient for the dissolution 
test. A flow-through sample holder could be a suitable setup, albeit one that is only able 
to perform at room temperature. 
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It is clear that particle engineering has a large part to play in the formulation of dry powder 
particles for inhalation. As a facile, one-step process suitable for drying solutions and 
suspensions into dry particles, spray drying is an invaluable technique for formulating dry 
powder particles for inhalation (Seville et al., (2007); Vehring, (2008)). One of the main 
attractions of spray drying as a manufacturing technique is that it is a scalable process 
5 PRELIMINARY TERAHERTZ TIME-
DOMAIN SPECTROSCOPY ON 
PREDICTING THE 
CRYSTALLISATION OF 
AMORPHOUS FORMULATIONS 
5.1 Predicting crystallisation of amorphous formulations 
5.1.1 Introduction 
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which provides the user control over the particle size, size distribution, morphology, 
moisture content and surface properties of the powders by tuning the spray drying 
temperature, aspirator flow rate, atomising gas flow rate and the feed flow rate of the 
stock solution into the spray dryer. Indeed, spray-drying is used for many other diverse 
applications such as food production (milk powders, instant coffee), catalyst supports and 
paint pigment production. 
One of the foremost concerns regarding spray-dried formulations is that the product is 
usually amorphous. This constitutes a challenge to the physical stability of the 
formulations as the amorphous state will tend to the more thermodynamically stable 
crystalline state with time. This is undesirable in the pharmaceutical field where active 
ingredients in the amorphous and crystalline form often have very different 
pharmacokinetic and pharmacodynamic profiles. Amorphisation is a key strategy in the 
formulation of poorly water-soluble drugs, with the bioavailability enhancement that the 
metastable amorphous form brings. Especially pertinent for pulmonary delivery, the 
surface characteristics of spray-dried powders have a sizeable influence on the FPF. Re-
crystallisation of spray-dried particles could affect the particle surface and hence its FPF 
(Maa et al., (1998)). 
According to the World Health Organization (WHO)’s guidelines for the “Stability 
testing of active pharmaceutical ingredients and finished pharmaceutical products” (WHO 
Stability Guide Annex 2 Stability testing of active pharmaceutical ingredients and 
finished pharmaceutical products, (2009)), stability testing at stress test conditions 
usually involves storing the pharmaceutical product at storage conditions that test its 
thermal stability and (if necessary) its moisture sensitivity. At regular intervals up to six 
months in duration, the samples have to be tested to determine if “significant change” has 
occurred in the key attributes of the product that may “affect its quality, safety and/or 
efficacy”. These tests can take up to a year to conduct and constitute a large part of the 
characterisation of a new pharmaceutical product formulation.  
Molecular motions are one of the mechanisms in the crystallisation of amorphous solids. 
Primary (α) and secondary (β) relaxations both take place for amorphous compounds and 
of particular interest are the Johari-Goldstein (JG) β-relaxations, which are a peak in 
mechanical or dielectric loss at a particular frequency. These relaxations are typically 
observed using dielectric spectroscopy, although recent studies have shown that neutron 
and light scattering (Ngai, (2004); Sokolov et al., (2001)), as well as terahertz time-
domain spectroscopy (THz-TDS),  are also sensitive to changes in molecular dynamics.  
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In their study of amorphous polyalcohols, Sibik et al. found three features in the dielectric 
losses shown in Figure 5.1. The vibrational density of states (VDOS) peak is noted at 
temperatures below Tg and is independent of temperature. The origins of this peak are due 
to libration-vibration (rotating slightly back and forth) motions which can be found in 
disordered solids but not in crystals. When T was between ~0.67 Tg and Tg, a temperature-
dependent β-relaxation could be observed. This was mainly ascribed to JG β-relaxation. 
α-relaxation processes were found above Tg. The paper also described that changes in the 
hydrogen-bonding of the samples played a role in the thermal related changes of the α 
and β-relaxations. Recently, Sibik et al., 2015 were able to demonstrate that the three 
temperature regimes displayed for amorphous polyalcohols were also present in 
amorphous drug molecules. 
 
Figure 5.1. Schematic of the thermal decoupling of the molecular relaxation processes 
from the VDOS or microscopic peak, in supercooled hydrogen-bonded liquids (Used with 
permission from Sibik et al., 2014).  
It is traditionally believed that storing amorphous systems at temperatures below their Tg, 
and at low humidty will reduce the risk of recrystallisation. The Kauzmann temperature, 
roughly estimated as Tg – 50 °C (Hancock et al., (1995); Hancock and Zografi, (1997); 
Zhou et al., (2002)), was assumed to be a temperature below which amorphous systems 
would be stable (Kauzmann, (1948)). However, it is now known that, even at those 
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temperatures, there may be sufficient molecular mobility, which results from JG-β 
relaxation (Bhattacharya and Suryanarayanan, (2009); Grzybowska et al., (2010); Hikima 
et al., (1999); Okamoto and Oguni, (1996)), for the systems to crystallise.  
While these relaxations are typically observed using methods such as dielectric 
spectroscopy, recently, Sibik et al., 2015 described using THz-TDS as a technique to 
predict crystallisation of amorphous drugs, given its ability to accurately measure the 
onset of local mobility in an amorphous system. When comparing between different 
amorphous systems, the study established a correlation between the thermal gradient of 
terahertz absorption and the physical stability of the samples (Figure 5.2). It was found 
that the greater the thermal gradient between the temperature range of Tgβ and Tgα, the 
greater the contribution of local mobility which may facilitate crystallisation, and hence, 
the poorer the physical stability of the system. 
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Figure 5.2. Absorption of amorphous paracetamol, flufenamic acid, indomethacin and 
simvastatin at 1.0 THz. For each sample the absorption coefficient, α, is rescaled by its 
low temperature average α0. The temperature is rescaled by Tg (=Tgα) and the solid lines 
represent linear fits. Paracetamol and flufenamic acid both exhibit a large increase in 
absorption upon heating between Tgβ and Tgα. They are highly unstable and recrystallise 
within a few minutes at ambient conditions. In contrast, simvastatin shows only a small 
increase in terahertz absorption upon heating between Tgβ and Tgα and remains amorphous 
for over 220 days under ambient conditions. Indomethacin represents an intermediate 
case, staying stable for about 7 days before recrystallisation (Used with permission from 
(Sibik and Zeitler, (2016)). 
This method offers a useful complementary technique, which is also more cost effective 
and easier to use than methods such as neutron and light scattering (Sibik and Zeitler, 
(2016)), to predict the physical stability of APIs, giving an insight into the molecular 
dynamics that underpin this. It could be utilised as a “first-pass” test to screen drugs for 
their physical stability before expanding research on the more promising candidates. 
However, the study only performed studies on pure drug particles whereas a typical 
commercial product will contain several other excipients together with the active 
ingredient.  
Here, we tried to build on that work by testing the spray-dried hybrid formulations of CS, 
BSA and PVA examined in Chapter 2.8.1 with the THz-TDS system. This pulmonary 
drug delivery system, with two different excipients, is a more accurate analogue for a 
commercially available pharmaceutical product. In this study, THz-TDS was used to 
predict the stability of these pulmonary delivery systems to investigate its applicability as 
a part of the stability testing regime for pharmaceutical products.  
CS was supplied by Sanofi-Aventis (Paris, France) while PVA (MW 88,000) was 
supplied by Tokyo Chemical Industry Co. Ltd (Tokyo, Japan). BSA was procured from 
Sigma-Aldrich (St. Louis, MO, USA). Potassium dihydrogen phosphate (Alfa-Aesar, 
Ward Hill, MA, USA) and sodium hydroxide (Merck KGaA, Darmstadt, Germany) were 
used to make pH 7.4 phosphate buffer solution (PBS). All water used throughout was 
5.1.2 Materials and Methods 
5.1.2.1 Materials 
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purified via reverse osmosis by an ELGA PURELAB Option-Q (Veolia Water, Paris, 
France) purification system. 
Formulation 1 (CS-SD), Formulation 2 (CS/BSA-50/50-SD), Formulation 3 (CS/PVA-
50/50-SD), Formulation 4 (CS/BSA/PVA-20/64/16-SD), Formulation 8 (CS/BSA/PVA-
50/25/25-SD), Formulation 9 (CS/BSA/PVA-80/10/10-SD) from Chapter 2.8.1 were 
analysed in this study. Details of their preparation were shown in Section 3.2.2.1. 
Powder X-ray diffractograms were obtained for the co-spray dried particles prior to THz-
TDS analysis using an X-ray diffractometer (D8 ADVANCE, Bruker Corporation, 
Madison, WI, USA) in steps of 0.05° using Cu Kα radiation as the X-ray source. The 
measurement conditions were as follows: target, Cu; filter, Ni; voltage, 40 kV; current, 
40 mA; scanning speed, 7.5°/min 
The co-spray dried powders were stored under the same conditions as for the BDP 
samples detailed in Section 4.2.2.5. 
The thermal profile of the powders was determined by DSC and MDSC. Experiments 
were conducted on a TA Instruments Q2000 Differential Scanning Calorimeter (New 
Castle, DE, USA). Approximately 3-5 mg of powder was placed into a Tzero® aluminium 
pan and a lid was crimped on. An empty pan was used as reference. Measurements were 
taken in DSC mode with a heating rate of 10 °C/min, and in modulation mode with a 
heating rate of 5 °C/min, and modulation of ± 0.5 °C every 100s. Tg was determined by 
analysing the reversing heat flow signal. 
The THz-TDS setup used is a standard transmission spectrometer that makes use of a 
5.1.2.2 Methods 
5.1.2.2.1 Preparation of amorphous pulmonary drug delivery systems 
5.1.2.2.2 Powder X-ray diffraction (XRD) 
5.1.2.2.3 Stability testing 
5.1.2.2.4 Determination of glass transition temperature 
5.1.2.2.5 Temperature controlled terahertz time-domain spectroscopy (THz-TDS) 
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wide gap photoconductive antenna to generate THz pulses and a ZnTe crystal for electro-
optic detection (Figure 5.3).  
 
Figure 5.3. (a) Schematic and (b) image of the THz-TDS setup used. Solid and dashed 
red lines represent optical pump and probe laser beams respectively. Blue lines represent 
terahertz beam. 
The variable temperature measurements were carried out using a modified Janis ST-100 
FTIR cryostat (Janis, Wilmington, USA; Figure 5.4). The cryostat was secured through 
an opening in the lid of the sample chamber and was cooled with a continuous flow of 
liquid nitrogen. Before cooling the cryostat, the sample chamber was evacuated with a 
(a) 
(b) 
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vacuum pump to 2 mbar. The temperature was monitored by a Lakeshore 331 temperature 
controller (Lakeshore, Westerville, USA) and was measured with a thermocouple and a 
silicon diode which was attached to the end of the cold finger of the cryostat. Heating was 
also achieved using the temperature controller which was attached to cartridge heaters on 
the cryostat.  
 
Figure 5.4. Image of cryostat used for THz-TDS measurements. 
The hybrid formulation powders were pressed into 13 mm pellets using a hydraulic pellet 
press (Specac Ltd, Kent, UK) and a 13 mm die. The powders were subjected to 2-3 tonnes 
of force for 3-5 minutes in order to form well-compacted pellets which were then mounted 
onto an oxygen-free copper sample mount at the end of the cryostat with individual 
copper sample holders (Figure 5.5). These sample holders consisted of two separate 
copper pieces with 13 mm holes to hold the pellets, and can be directly screwed onto the 
sample mount. The pellets were sandwiched between two z-cut quartz windows onto the 
sample holders which were then screwed to the sample mount. A sample holder bearing 
a pair of quartz windows was used as a reference. Further details can be found in (Parrott 
et al., (2009); Sibik, (2014); Tan, (2015)). 
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Figure 5.5. Image of copper sample mount with sample holders. 
Terahertz spectra were acquired in the frequency range of 0.2-2.5 THz over a temperature 
range of 80 K to 430 K. Terahertz frequency data was extracted from the time-domain 
data (Duvillaret et al., (1996)) and the spectral absorption coefficient, α, at 1 THz was 
analysed as a function of temperature. 
All the tested formulations were examined for their crystalline content before THz-TDS 
studies and found to be X-ray amorphous as shown in Figure 5.6.   
 
Figure 5.6. X-ray diffractograms of amorphous spray-dried formulations. 
Thereafter, the formulations were stored at accelerated stress conditions of 40 °C/75% 
5.1.3 Results and Discussion 
5.1.3.1 Crystallinity of Formulations 
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RH as recommended by the ICH Q1A (R2) guidelines. After storage for 14 days, their X-
ray diffractograms can be seen in Figure 5.7. As can be seen, the initially amorphous 
formulations had all crystallised. 
 
Figure 5.7. X-ray diffractograms of co-spray dried formulations after storage at 
accelerated stress test conditions of 40 °C/75% RH for 14 days.  
As previously discussed in Section 3.3.3, the Tg of CS had not been previously reported 
due to the large evaporation endotherm overlapping with the glass transition. Using 
MDSC, we were able to determine the Tg of amorphous spray-dried CS as well as the co-
spray dried hybrid formulations. The Tg was determined from the reversing heat flow 
signal (which contains heat capacity related events such as the glass transition) of the 
MDSC thermograms and shown in Figure 5.8. The glass transition of amorphous spray-
dried CS was previously discussed and can be referred to in Section 3.3.3.  
 
5.1.3.2 Determination of glass transition temperature 
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Figure 5.8. MDSC thermograms of (a) CS/BSA-50/50-SD, (b) CS/PVA-50/50-SD, (c) 
CS/BSA/PVA-20/64/16-SD, (d) CS/BSA/PVA-50/25/25-SD, and (e) CS/BSA/PVA-
80/10/10-SD with inset of glass transition. Total heat flow represented with (• • • •), non-
reversing heat flow with (▬ ▬), and reversing heat flow with (▬▬). 
(a) 
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Figure 5.8. MDSC thermograms of (a) CS/BSA-50/50-SD, (b) CS/PVA-50/50-SD, (c) 
CS/BSA/PVA-20/64/16-SD, (d) CS/BSA/PVA-50/25/25-SD, and (e) CS/BSA/PVA-
80/10/10-SD with inset of glass transition. Total heat flow represented with (• • • •), non-
reversing heat flow with (▬ ▬), and reversing heat flow with (▬▬). 
(b) 
(c) 
Chapter 5: Preliminary terahertz time-domain spectroscopy on predicting the crystallisation of amorphous 
formulations 
Leonard Chia - February 2018   125 
 
Figure 5.8. MDSC thermograms of (a) CS/BSA-50/50-SD, (b) CS/PVA-50/50-SD, (c) 
CS/BSA/PVA-20/64/16-SD, (d) CS/BSA/PVA-50/25/25-SD, and (e) CS/BSA/PVA-
80/10/10-SD with inset of glass transition. Total heat flow represented with (• • • •), non-
reversing heat flow with (▬ ▬), and reversing heat flow with (▬▬). 
As can be noted, the Tg of CS/BSA-50/50-SD (60.7 °C) was similar to that of CS-SD 
(57.9 °C), but the addition of PVA to CS caused the Tg to drop to ~40 °C, where it 
(d) 
(e) 
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remained for the hybrid formulations, despite the addition of BSA.  
The terahertz absorption spectra of the amorphous spray-dried formulations at 1.0 THz 
can be seen in Figure 5.9. Here, the absence of the distinct temperature regimes as noted 
by Sibik et al. is prominent. In fact, the THz absorption even drops where it was expected 
to rise relatively strongly with increasing temperature above Tg. This effect was 
determined to be related to the water content in the formulations and was resolved by 
drying the highly hygroscopic formulations over phosphorus pentoxide (P2O5) prior to 
analysis as seen in Figure 5.10. The decrease in terahertz absorption is no longer present. 
Similar behaviour was found when the experiment was repeated for CS/BSA-50/50-SD, 
CS/PVA-50/50-SD and CS/BSA/PVA-50/25/25-SD (not shown).  
 
Figure 5.9. The change in absorption coefficient, α, at 1.0 THz as a function of 
temperature for a range of formulations. Samples were measured without any prior drying 
of the sample pellets. The absorption coefficient is rescaled by the low-temperature 
average α0; the temperature is rescaled by Tg.  
5.1.3.3 THz-TDS Spectroscopy 
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Figure 5.10. Terahertz absorption spectra of CS-SD at 1.0 THz. Filled crosses indicate 
when the sample was dried with P2O5 prior to analysis.  
The temperature regime identified by Sibik et al. as that of importance when comparing 
between different amorphous drugs was between Tgβ and Tgα, and was described to be 
between 0.67 Tgα and Tgα. Since then, it has been determined that Tgβ can be determined 
by dielectric spectroscopy to be when the JG β-relaxation time, τJG, reaches 100 s 
(Capaccioli et al., (2015)). From Figure 5.9, the range appeared to be between 0.6 Tgα and 
Tgα for the systems studied. That said, there was no significant difference in the terahertz 
absorption in this region for the different spray-dried formulations tested. This result is in 
keeping with the accelerated stress test XRD results seen in Figure 5.7, where all the 
formulations crystallised at the accelerated stress test storage conditions after just two 
weeks. 
However, the DSC thermograms seen in Figure 5.8 have a distinct lack of a crystallisation 
trough, which suggests that the amorphous solid does not crystallise with temperature in 
a dry environment, such as the N2 atmosphere in the DSC, and the vacuum of the THz-
TDS setup. Water has been shown to have an effect on the molecular mobility and 
physical stability of amorphous drugs (Mehta et al., (2016)) and as both the drug and 
excipients in the system studied are highly hygroscopic, the first stage of crystallisation 
may be water absorption and that with the plasticising effect of water, differences in the 
hydrogen-bonding and molecular mobility would be more pronounced if the conditions 
of the THz-TDS setup followed that of the accelerated stress test RH of 75% in a similar 
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way that McIntosh et al. performed with amorphous lactose. Thus, in the same way Sibik 
et al. used THz-TDS to predict the crystallisation of amorphous drugs by testing at a range 
of temperatures, one could modify the setup to test the molecular mobility of a 
formulation at different relative humidities to determine the conditions at which 
amorphous drug formulations should be packaged at in order to preserve their physical 
stability as well as the upper limit of RH that the formulation can be exposed to before 
crystallisation occurs. This could be a useful tool in the development of amorphous 
dispersions as increasing numbers of new drug entities display poor aqueous solubility 
and turn to amorphous formulations to increase their bioavailability. 
As the formulation of drugs become increasingly complex, having to work around the 
unfavourable nature of new drug entities, one has to be careful to ensure that the efficacy 
of the new formulation is preserved over time. As a relatively simple technique to increase 
solubility and dissolution rate, amorphisation of crystalline drugs is widely utilised to 
formulate poorly aqueous soluble drugs. Their inherent physical instability is a huge 
drawback as the metastable drugs tend to the lower energy and stable crystalline form. 
Accelerated stress tests have been devised to reduce the amount of time needed to probe 
a formulation’s stability over time to determine its packaging and handling requirements, 
but this test still requires six months of testing. A rapid and simple method to predict a 
formulation’s crystallisation tendency would be very useful for formulators to eliminate 
formulations with poor stability without having to undergo six months of testing. THz-
TDS is a novel technique which could fulfil that role and although the initial testing 
conditions for the spray-dried CS formulations can be improved further, promising data 
was obtained in which drug formulations with several components were analysed, 
showing that the technique could be applied to formulations as well as pure drugs. 
Although it must be emphasised that terahertz analysis will not provide a complete picture 
of all the factors governing crystallisation, it is hypothesised that a redesigned setup could 
be used to study the changes in the molecular dynamics of the formulations and how it 
may facilitate the crystallisation of amorphous formulations, and thus be a very useful 
complementary technique in the characterisation of amorphous formulations. 
5.1.4 Conclusions 
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Pulmonary drug delivery has been championed for various reasons: circumvention of 
hepatic first pass metabolism, localised treatment of respiratory diseases which reduces 
systemic exposure and thus side effects, a large absorptive surface with a thin diffusion 
path for systemic circulation, and a non-invasive route to deliver drugs.  
However, pulmonary drug delivery is limited by robust clearance mechanisms in the 
lungs, such as mucociliary clearance in the upper airways and phagocytosis by alveolar 
macrophages in the alveoli. An optimal release of active ingredients in the lung – where 
the rate of absorption is not too fast to induce an adverse reaction from excessive drug 
concentrations, or too slow to not reach therapeutic levels – can help to improve the 
therapeutic outcome of pulmonary drug delivery as well as improve patient convenience 
and compliance by requiring less frequent dosing. It is also imperative to develop cost-
effective inhaled therapy for the unmet needs of developing nations, where the bulk of 
respiratory-related deaths from asthma and COPD occur. Controlled pulmonary delivery 
in those countries could bring about benefits of not requiring a trained medical 
professional to administer medication, in addition to the aforementioned benefits.  
In this study, two controlled pulmonary delivery systems were developed and 
characterised for their efficacy in delivering drugs of two different natures – water-soluble 
and poorly water-soluble – in a controlled manner. 
For the control of a water-soluble drug, a commonly used pharmaceutical excipient, PVA, 
was utilised to modulate the release of an anti-asthma drug, cromolyn sodium. A protein, 
6 CONCLUDING REMARKS 
6.1 Modulation of drug release from a water-soluble drug 
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BSA, was also incorporated into the formulation to impart superior aerosolisation 
properties. The two excipients and the drug were mixed and spray-dried in varying 
quantities to produce aerosol powders. The effect that each component had on the overall 
performance of the controlled pulmonary delivery system was then determined, 
especially for aerosol performance and dissolution rate. 
It was found that there is a complex interplay between the two excipients, who although 
have complementary features such as dissolution rate modulation and increased 
aerosolisation ability, have other characteristics which affect the desired attribute of the 
other excipient. The drug itself has an influence on the performance of the overall system, 
and finding an optimal balance between the merits and demerits of each component in the 
system is a complex task. 
A poorly water-soluble drug, beclomethasone dipropionate (BDP), was formulated with 
a commercially available graft co-polymer, Soluplus®. Soluplus® is an amphiphilic 
polymer with a bifunctional character, capable of forming solid solutions and solubilising 
poorly water-soluble drugs in an aqueous environment through the formation of micelles. 
Soluplus® has been found to be suitable for the delivery drugs to the lung in low 
concentrations, as corticosteroids usually are (Andrade et al., (2015)). The drug and 
polymer were spray-dried to produce aerosol powders which were then evaluated for 
aerosol performance properties as well as dissolution and solubility enhancement. 
It was found that the Soluplus® has the ability to increase the solubility and dissolution 
rate of BDP to a certain extent, but due to limitations in the USP dissolution apparatus 4 
(flow-through cell) to accurately mimic the physiological conditions in the lung, and also 
the inherent properties of Soluplus®, the solubility and dissolution rate enhancements 
were less than expected. It was found that Soluplus® may form gels at physiological 
temperature, and in low amounts of dissolution medium. While this property is not 
beneficial for dissolution rate enhancement, it could find use in modulating the release of 
drug through the gel structure.  
The physical stability of the spray-dried formulations was also probed. As the amorphous 
spray-dried powders would be expected to achieve a faster dissolution rate and higher 
apparent solubility due to the metastable amorphous state, it is imperative that the state is 
preserved for the formulation to work effectively over a period of transport and storage. 
6.2 Dissolution rate and solubility enhancement of a poorly water-soluble 
drug 
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It was found that the amorphous powders were able to retain its amorphous character up 
to 9 months at accelerated stress test conditions, with a drug loading of up to 15% (w/w), 
displaying the formulations’ potential as a controlled pulmonary delivery system. 
Spray drying is an industrially viable, facile manufacturing process capable of forming 
dry powders from a solution or suspension in a single step. Due to the quick drying time 
of the feed, the powders formed are usually in the amorphous form. While the amorphous 
form brings about benefits such as dissolution rate enhancement and increased solubility, 
it is inherently unstable and tends to revert to its more thermodynamically stable 
crystalline form over time. This crystallisation may bring about undesired properties to 
the dry powders, affecting the morphology and surface characteristics, which in turn 
affect the powders’ aerosol performance. 
The importance of the physical stability of the formulations cannot be understated and 
amorphous formulations are typically subjected to stability tests to determine its physical 
stability. These tests last for a minimum of six months under accelerated stress test 
conditions. The ability to predict the physical stability of amorphous formulations would 
be hugely beneficial to a formulation scientist, not especially given that a majority of 
drugs in the pharmacopoeia are poorly water-soluble and amorphisation is one of the 
leading strategies to formulate such drugs. 
A novel method using terahertz time-domain spectroscopy (THz-TDS) to predict the 
physical stability of amorphous drugs was developed by Sibik et al., (2015). However, 
the method was only applied to pure, amorphous drugs, and not to multi-component 
formulations. This novel system was tested on the amorphous spray-dried hybrid 
formulations of CS, BSA and PVA. The formulations all displayed a similar absorption 
of THz, indicating a similar physical stability. The accelerated stability tests confirmed 
that all the initially amorphous spray-dried hybrid formulations all crystallised over a 
period of 12 months, agreeing with the THz-TDS data. However, a potentially useful 
modification could be made to the apparatus to investigate the terahertz absorption over 
a range of relative humidities instead to better analyse hygroscopic formulations such as 
the ones tested. Nonetheless, the technique shows the ability to analyse formulations as 
well as pure drugs, and much promise as a complementary tool in a formulation scientists’ 
tool box, possibly as an initial screening test for amorphous formulations. 
6.3 Probing the physical stability of amorphous aerosol powders 
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For the hybrid protein-polymer particles investigated in Chapter 3, a formulation with a 
similar protein/polymer ratio but with an increased drug loading between 20% (w/w) and 
50% (w/w) could be tested as the increased drug loading should increase the amount of 
CS released, albeit while reducing the FPF. It is this careful balance that needs to be 
maintained in considering formulations with excipients that appear to be both 
complementary and contradictory to each other.  
It is clear that the inability to comprehensively probe the dissolution profile of the BDP- 
Soluplus® system in Chapter 4 clouded the study of what may be a promising system to 
improve the dissolution rate of a poorly water-soluble drug for pulmonary delivery. To 
gain a better understanding of the unexpected low amount of drug dissolved during the 
dissolution test, the aliquots could be examined to determine the formation of micelles 
(using dynamic light scattering) and further, the ability of the micelles to solubilise the 
drug by testing its crystallinity with small angle x-ray spectroscopy (SAXS). SAXS could 
also be used to study the formation of gel formed within the cells of the dissolution 
apparatus. This could help in the identification of steps to minimise its formation and also 
to confirm that the gel is indeed responsible for the limited release of active ingredient 
for the dissolution test, hence improving the conduct and accuracy of the dissolution test.  
Developing controlled pulmonary drug delivery systems is a complex process with many 
different factors to consider. The studies performed here have gone some way to better 
understanding the mechanisms and properties governing each formulation. As no perfect 
formulation exists, the difficulty is in developing an optimal blend of beneficial 
characteristics for a suitable pulmonary drug delivery system, which will doubtless bring 
many benefits to any sufferer of respiratory disease, with promise for the systemic 
delivery of drugs and vaccines. 
6.4 Future work 
6.5 Final comments 
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